Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2016

The Role of N-acetyl-L-Cysteine (NAC) as an Adjuvant to Opioid
Treatment in Patients with Inadequately Controlled Chronic
Neuropathic Pain
Thomas B. Moore
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Clinical Psychology Commons, Health Psychology Commons, and the Pain Management
Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/4315

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

THE ROLE OF N-ACETYL-L-CYSTEINE (NAC) AS AN ADJUVANT TO OPIOID
TREATMENT IN PATIENTS WITH INADEQUATELY CONTROLLED CHRONIC
NEUROPATHIC PAIN

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

By: Thomas Burton Moore
Bachelor of Arts, The Evergreen State College, 2003
Master of Science. Northeastern University, 2007

Director: Dace S. Svikis, Ph.D.
Professor of Psychology, Psychiatry, and Obstetrics/Gynecology
Department of Psychology and Psychiatry

Virginia Commonwealth University
Richmond, Virginia
April, 2016

ii
Acknowledgments
Writing of this dissertation only occurred through the support from my advisors, family, and friends.
First and foremost is the unwavering patience, support, and encouragement that I received from my
amazing, and ultimately more intelligent, wife. She has supported me in every possible way
throughout this process and I could not have completed this without her.
I would like to express my deepest gratitude to my advisor, Dr. Dace Svikis for her wealth of
experience and her seemingly limitless patience and optimism as we worked through many, many
drafts. I will also never forget the reminders to not compare “apples and oranges” as well as not
losing the “forest for the trees”. Throughout this process I have learned, often through trial and
error, how to write a full manuscript.
I would like to recognize Dr. Jim McCullough, the very best clinical supervisor I have had the
privilege to work with. Your energy and enthusiasm has been a great support over the past several
years.
Lastly, but certainly not least, I would like to thank my dissertation committee members Drs. Svikis,
Dillon, Phipps, Weaver and McCullough. This project has been a long time in the works and it was
made measurably better by the guidance and input I received. Thank you.

iii
Table of Contents
Page
Acknowledgements…………………………………………………………………………….….ii
List of Figures….…………………………………………………….……………………..……..v
List of Tables……………………………………………………………………………..….......vii
Abstract……………………………………………………………...…………………………..viii
Introduction……...…………………………………………………………………………..…….1
Review of the Literature…………………………………………………………………..………5
Chronic Pain………………………………………………………………………...…………5
Measurement of Treatment Efficacy……………………………………….………..………10
Etiology of Chronic Pain…………………………………………………………...………..14
Catastrophizing……………………………………………………………………..………..22
Health Related Quality of Life……………………………………………………..………...27
N-acetyl-L-cysteine………………………………………………………………..…………29
Statement of the Problem and Hypotheses……………………………………………...……….34
Hypotheses………………………………………………………………………....…...……36
Methods.………...……………………………………………………………………..…………38
Study Design and Overview……………………………………………………..……..……38
Participants.……………………………………………………………………..……………43
Procedure.……………………………………………………………………….………...…45
Measures and Participant Information ………………………………………………………51
Data Analysis Plan…………………………………………………………………..….……56
Results……………………………………………………………………………………….……57
Data Analysis……………………………………………………………………………...….57
Characteristics of Sample……………………………………………………………….……58
Primary Analyses……………………………………………………………………….…….64
Summary of all Participants…………………………………………………...……….……..84
Case Studies…………………………………………………………………………….…….86
Discussion………………………………………………………………………………….….....99
NAC and use of PRN opioid medication……………………………………………………100
NAC and pain severity ratings……………………………………………………………....102
NAC and Quality of Life………………………………………………………………...….103
Catastrophizing and response to NAC……………………………………………………....105
Lessons Learned: Informing Future Research……………………………………….…..…106
Study Limitations……………………………………………………………………...……119
Study Strengths……………………………………………………………………………..120

iv
List of References……………………………………………………………………………..123
Appendix…………...………………………………………………………………………....144
Vita……………………………………………………………………………………………154

v
List of Figures
Figure 1. Examples of operant conditioning procedures in chronic pain………………………...16
Figure 2. The biopsychosocial model of chronic pain……………………………………………18
Figure 3. Fear avoidance model of chronic pain…………………………………………………19
Figure 4. Study Flow Chart……………………………………………………………………….38
Figure 5. CONSORT diagram …………………………………………………………………...43
Figure 6. Study procedures and measures by study visit…………………………………………46
Figure 7. Mean daily MEDs across 3 study phases………………………………………………65
Figure 8. Mean Average pain ratings across 3 study phases……………………………………..66
Figure 9. Mean Highest pain ratings across 3 study phases……………………………………...67
Figure 10. Average VAS ratings across all study visits………………………………………….68
Figure 11. Highest VAS across all study visits…………………………………………………..70
Figure 12. Lowest VAS ratings across all study visits…………………………………………...71
Figure 13. Average VAS ratings across 3 study phases………………………………………….72
Figure 14. Highest VAS ratings across 3 study phases…………………………………………..73
Figure 15. Least VAS ratings across 3 study phases……………………………………………..74
Figure 16. PCS scores across 3 study phases…………………………………………………….77
Figure 17. MCS scores across 3 study phases…………………………………………………...78
Figure 18. Average VAS ratings across three time points for Low and High catastrophizers…..80
Figure 19. Worst VAS ratings across three time points for Low and High catastrophizers……..81
Figure 20. Least VAS ratings across three time points for Low and High catastrophizers……...83
Figure 21. VAS ratings provided by participant #017……………………………………………88
Figure 22. Pain catastrophizing scores for participant #017……………………………………...89
Figure 23. PHQ-9 scores of depression for participant #017……………………………………..89
Figure 24. Pain disability for participant #017…………………………………………………..90

vi
Figure 25. Perceived Stress Scale for Participant #017………………………………………….90
Figure 26. VAS ratings provided by participant #007……………………………………………92
Figure 27. Pain catastrophizing scores for participant #007……………………………………..92
Figure 28. Perceived Stress Scale for Participant #007…………………………………………..93
Figure 29. Pain disability for participant #007…………………………………………………...93
Figure 30. PHQ-9 scores of depression for participant #007…………………………………….94
Figure 31. VAS ratings provided by participant #024……………………………………………96
Figure 32. Pain catastrophizing scores for participant #007……………………………………..96
Figure 33. Perceived Stress Scale for Participant #024…………………………………………..97
Figure 34. Pain disability for participant #024…………………………………………………...97
Figure 35. PHQ-9 scores of depression for participant #024…………………………………….98

vii
List of Tables
Table 1 Prevalence rates for study exclusion criteria in a chart review sample of N =1072
patients with an opioid prescription……………………………………………………….40
Table 2. Participant Characteristics: Initiated NAC (n =11) and Enrolled (N=28)……………...59
Table 3. ID-Pain responses..................................................................................................60
Table 4. Percentage of ID-PAIN responses endorsed.............................................................60
Table 5. Pain medications prescribed at study enrollment (N=28)………………………………61
Table 6. PRN opioid medications of participants initiating NAC (N=11)………………………62
Table 7. Stable pain medications of participants initiating NAC (N=11)………………………..62
Table 8. Stable and PRN pain medications of participants initiating NAC (N = 11)……………63
Table 9. Descriptive statistics for MEDs across study phases……………………………………64
Table 10. Descriptive statistics for Average pain ratings across 3 study phases…………………65
Table 11. Descriptive statistics for Highest pain ratings across 3 study phases………………….66
Table 12. Descriptive statistics for Average VAS ratings across all study visits………………...68
Table 13. Descriptive statistics for Highest VAS ratings across all study visits………………...69
Table 14. Descriptive statistics for Least VAS ratings across all study visits……………………70
Table 15. Descriptive statistics for Average VAS ratings across 3 study phases………………..72
Table 16. Descriptive statistics for Highest VAS ratings across 3 study phases………………..73
Table 17. Descriptive statistics for Least VAS ratings across 3 study phases…………………..74
Table 18. Pain catastrophizing and Average VAS pain ratings across 3 time points……………79
Table 19. Pain catastrophizing and Worst VAS pain ratings across three time points…………..81
Table 20. Pain catastrophizing and Least VAS pain ratings across three time points……………82

viii
Abstract

The Role of N-acetyl-L-Cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients with
Inadequately Controlled Chronic Neuropathic Pain

By Thomas Burton Moore, M.S.

A dissertation submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2016

Major Director: Dace Svikis, Ph.D.
Professor of Psychology, Psychiatry, and Obstetrics/Gynecology
Department of Psychology and Psychiatry

Introduction. While opioid medications are commonly prescribed for management of neuropathic
pain (NP), long-term use has been associated with increased risk for overdose, drug interactions and
addiction. New strategies are necessary to better manage chronic pain, thereby reducing need for
opioid medications and their associated adverse consequences. N-acetyl-L-cysteine (NAC), an overthe-counter supplement, has shown promise in the treatment of psychiatric and addictive disorders.
In addition, NAC has shown promise for reducing physiological signs of NP in laboratory rat
models, prompting this study.

Purpose. The present study was an open-label clinical trial of NAC as an adjuvant to opioid
treatment for poorly controlled, chronic NP. It examined whether 1200 mg NAC twice daily for 4
weeks was associated with: lower ratings of patient-reported pain; reductions in PRN opioid
medication for breakthrough pain; and improvements in physical and mental health quality of life
(QoL). The study also examined whether appraisal of pain impacts response to medication.

ix

Method. Participants were N=28 chronic NP patients who consented to study participation. This
consisted of 2 baseline assessments, 4 weeks of NAC and 1 post-trial follow-up visit. The majority
(N=17) dropped out or were excluded during baseline. Of the remaining participants, N = 11 started
the study medication and N=10 completed the study, with daily recordings of pain severity ratings
and use of PRN opioid medication. Small sample size limited analyses to qualitative case reviews
and effect sizes.

Results. Over 90% of participants receiving NAC completed the study. Case review found varied
results. While 4 of 10 participants showed decrease in average pain ratings during NAC, estimated
effect sizes for the whole sample were small, bordering on negligible (ω² from .003 to .027) as were
those for PRN opioids (Partial Eta-Squared=.0003). Effect size for mental health QoL was medium
(Cohen's d=.421).

Conclusions. With N=10, findings must be interpreted with caution. Nonetheless, the study found
some albeit small evidence supporting NAC for improving mental health QoL and pain ratings.
Several participants reported improvements in pain and mental health domains while taking NAC.
NAC was well tolerated with minimal side effects. Lessons from this study will inform design and
implementation of future NAC studies.

The Role of N-acetyl-L-Cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients with
Inadequately Controlled Chronic Neuropathic Pain

Pain is an integral part of life and is essential for survival, however, for many, it progresses
beyond an acute condition and into a serious, debilitating, and chronic problem with little or no
relief. It is estimated that between 19% and 25% of the U.S. population has chronic or recurrent
pain, 10% report pain lasting a year or more, and 40% of the U.S. population report that pain had a
moderately or severely degrading impact on their life (National Center for Health Statistics [NCHS],
2004; Kennedy, Roll, Schraudner, Murphy & McPherson, 2014)
Chronic pain is a general term that includes a large sample of diseases, illnesses, disorders
and traumas (Turk & Melzack, 2011). A subset within the chronic pain grouping is chronic
neuropathic pain. Neuropathic pain, or neuropathy, is defined by the International Association for
the Study of Pain as "pain arising as a direct consequence of a lesion or disease affecting the
somatosensory system" (Treede et al., 2008). A number of conditions can cause neuropathic pain
and it is present in approximately 1-8% of the general population (van Hecke et al., 2014; Dworkin
et al., 2007; Torrance, Smith, Bennett & Lee, 2006; Bouhassira, Lantéri-Minet, Attal, Laurent &
Touboul, 2008). Neuropathic pain is generally very difficult to treat, and there are very few
approaches available to prevent the development of neuropathic pain.
The range of diseases, illnesses and injuries which can result in neuropathic pain present a
significant challenge in diagnosis and treatment in the clinical setting, and measurement in the
research setting. While numerous treatments are available, patient response to these treatments are
extremely variable and there is little understanding of which patients will benefit from a particular
treatment. Complicating this further is that a portion of individuals receiving treatment will not
receive any benefit from any of the available treatment approaches. A lack of response to the
traditional treatment approaches, such as SSRIs, will often result in the transition to the use of long
1

term opioids for the management of pain. Patients utilizing long term opioid treatment for the
management of their pain will often receive additional as-needed opioid medication to treat periods
of increased, or breakthrough, pain.
Use of opioids in the management of chronic neuropathic pain is a common general practice
(Dworkin et al., 2010), however, it is not without controversy (Fields, 2011, Dowell, Haegerich &
Chou, 2016). Long term use of opioids presents some unique challenges. Management of pain is
essential; however, the possibility of tolerance and dependence is a very real concern for these
patients. Anywhere from 3-30% of patients prescribed long term opioids become dependent on
opioids (Boscarino et al., 2010; Elander, Lusher, Bevan & Telfer, 2003; Adams et al., 2006). This
concern has prompted the search for novel, non-narcotic, approaches to the management of
neuropathic pain for patients who do not respond to traditional treatments.
There are a number of challenges in testing the efficacy of novel treatment approaches to
chronic neuropathic pain. Research suggests that, for chronic pain patients, the psychological
aspects of pain are the most salient features of the pain response (Horstman & Flax, 1999; Beecher,
1956; Ferrari, 2002; Fields, 1991). There is growing literature highlighting the importance of
psychological factors in the experience of neuropathic pain, and in the assessment of these factors in
novel treatment approaches (Sullivan, Lynch & Clark, 2005; Haythornthwaite & Benrud-Larson,
2000; Danie et al., 2008; Sullivan, Lynch, Clark, Mankovsky & Sawynok, 2008). Among the
psychological factors that appear to impact the pain experience, the strongest empirical support is for
catastrophizing (Turner & Aaron 2001) and fear avoidance (Vlaeyen & Linton 2000). Furthermore,
it has been suggested in the research that the inclusion of assessments of Health-Related Quality of
Life (HRQoL), including social and emotional functioning, should be assessed when analyzing
analgesic efficacy (Baron, Binder & Wasner, 2010). Researchers have also suggested that the lack
of treatment efficacy found in novel analgesics may be due to a focus on limited variables (e.g. pain
level) and a lack of recognition of the importance of assessing multiple domains of functioning
2

beyond just the level of pain experienced (Foster, Hill & Hay, 2011; Turk & Okifuji, 2002; Turk &
Rudy, 1988).
The present study grew out of research on Reactive Oxygen Species (ROS) and their role in
the maintenance of chronic neuropathic pain (Kwak, Lim & Baek, 2011). N-Acetyl-L-cysteine
(NAC), a ROS scavenger, NAC has shown promise at reducing physiological signs of neuropathic
pain in laboratory rat models (Kim et al., 2004; Kim et al., 2006). In a human clinical trial
investigating this supplement, researchers found that NAC administered pre and post operatively
resulted in reductions in post-operative morphine use compared to a control group (Orban et al.,
2006). Additionally, this over-the-counter herbal supplement has shown some efficacy in the
reduction of cravings in patients with cocaine, marijuana, and nicotine addiction (Dean, Giorlando &
Berk, 2011). These findings prompted the present study of NAC for patients with inadequately
controlled chronic neuropathic pain.
The present study was the first to evaluate the potential benefits of NAC as an adjunct to
opioid treatment for patients with poorly controlled neuropathic pain. Bearing in mind the risks
associated with long-term opioid use, the importance of identifying nonopioid treatment alternatives
thereby reducing the need for opioids is imperative. The purpose of the present study is to examine
the addition of NAC to opioid treatment for poorly controlled, chronic neuropathic pain. We begin
with a review of the literature focusing on chronic neuropathic pain, multidimensional
measurement of pain outcomes, theories of chronic pain, and an overview of N-Acetyl-L-cysteine
research to date. Given the variability in response to treatments, and the difficulty in measuring
successful treatment response, the current study used several psychosocial variables to assess the
efficacy of a novel treatment approach.
In order to determine if NAC was a beneficial adjunct to opioid treatment in this population,
the following hypotheses were tested: 1) Compared to baseline, study participants will report a
reduction in their use of opioid medications to manage breakthrough pain, using measures of daily
3

morphine equivalent dose (MED). 2) Past week VAS severity ratings for Average, Worst and Least
amount of pain will be lower over the 4-week clinical trial period than those reported at baseline. 3)
Upon completion of the 4 week medication trial, participants will have higher physical and mental
health related quality of life scores (as measured by the Short Form-12 survey) than obtained at
baseline. 4) After completing the 4 week medication trial, participants with a more positive
appraisal of their pain (Low catastrophizers on the pain catastrophizing scale) will have lower Visual
Analogue Scale pain ratings than participants with more negative appraisals of their pain (High
catastrophizers). We reviewed the individual level data to further explore the clinical utility of NAC
as an adjunct to opioid treatment for chronic neuropathic pain and identify any trends in the data.
Finally, lessons learned from participant identification, study recruitment, baseline assessment
measures, retention of patients in the clinical trial and 1-month follow-up procedures will be
presented with focus on informing design and implementation of future NAC studies.

4

Review of the Literature
Chronic Pain
Chronic pain is a well-documented and prolific area of research. Chronic pain can consist of
a number of different pain experiences (i.e. neck pain, lower back pain, migraines, pelvic pain). By
definition it continues beyond the time expected, and shows few signs of going away (Friedman &
Silver, 2007). It is a complex condition, but pain is generally defined as chronic pain when it lasts
longer than six months (Turk, Wilson & Cahana, 2011). A number of different factors can result in
chronic pain, including tissue trauma, acute illness, inflammation and nerve damage (Turk &
Melzack, 2011). According to the National Center for Health Statistics (2006), approximately 25%
of the adult U.S. population has chronic or recurrent pain, and one in ten Americans reported
experiencing pain with duration of a year or more (Turk & Melzack, 2011). It is estimated that the
average prevalence of chronic pain across the globe is currently at 20% (Boris-Karpel 2010).
Chronic pain can contribute to declines in physical and social role functioning as well as
psychological stress and suffering. Furthermore, it is estimated that chronic pain costs our society
billions of dollars each year through lost work productivity, including unemployment and disability
benefits, and increased health care costs associated with having the disorder. According to the
Gaskin and Richard (2011, 2012), the cost of pain in the United States was recently estimated to be
between $560 and $635 billion annually, including direct health care expenditures of $261 to $300
billion. Chronic pain is such a far reaching and severe problem that the U.S. Congress designated
the period from 2001–2010 as the Decade of Pain Control and Research (Kerns, Sellinger & Goodin,
2011).

Neuropathic Pain. Chronic neuropathic pain is one particularly challenging subtype of
chronic pain and was the focus of the current study. The International Association for the Study of
Pain defines neuropathic pain as "pain arising as a direct consequence of a lesion or disease affecting
5

the somatosensory system" (Treede et al., 2008). A myriad of conditions can cause neuropathic
pain, or neuropathy, and it is typically the result of damage to the nervous system (e.g. the peripheral
nerve, the dorsal root ganglion or dorsal root, or the central nervous system) (Woolf & Mannion,
1999). Approximately one third of cases of neuropathy are the result of diabetes, while another third
of cases are the result of autoimmune disorders, tumors, heredity, nutritional imbalances, infections
or toxins and the remaining third of cases are idiopathic, or of an unknown cause (Loeser, 2001).
Given the range of diagnoses that can result in neuropathic pain, precise incidence rates are
not available, however in the general population, prevalence rates seem to be between 1% and 8%
(Dworkin et al., 2007; Bouhassira, Lantéri-Minet, Attal, Laurent & Touboul, 2008; Smith &
Torrance, 2012). Torrance and colleagues (2006) surveyed a random sample of 6,000 adults as part
of 6 family practices in 3 cities in the U.K. The authors mailed a validated survey, the Leeds
Assessment of Neuropathic Symptoms and Signs score (S-LANSS), for the identification of pain of
a predominately neuropathic origin. The authors found that of respondents (N=2,957) the
prevalence of any chronic pain was 48% and the prevalence of pain of predominantly neuropathic
origin was 8.2%. In a French study, a nationwide postal survey was conducted with a representative
sample of 30,155 subjects (Bouhassira, Lantéri-Minet, Attal, Laurent & Touboul, 2008). A
validated questionnaire, the Douleur Neuropathique 4 (DN4), was returned by 24,497 (81.2%) of
those sampled. The authors found that 31.7% of respondents reported any chronic pain and the
prevalence of pain of predominately neuropathic origin was 6.9%. Prevalence studies focused on
some of the more common conditions which result in neuropathic pain show that approximately
26.4% of individuals with type 2 diabetes experienced peripheral diabetic neuropathy (Davies,
Brophy, Williams, Taylor, 2006), 8.0% of individuals diagnosed with herpes zoster experienced
postherpetic neuralgia after 30 days (Choo, Galil, Donahue, 1997), and 37.0% of those with chronic
low back pain had a predominantly neuropathic component to their pain (Freynhagen, Baron,
Gockel, Tolle, 2006). These studies affirm the large variability in the development of neuropathic
6

pain conditions. Such variability among subgroups of neuropathic pain demonstrates the complexity
of this disorder, and makes research difficult. While exact numbers of remittance in chronic
neuropathic pain is unknown, one small study (N=29) found that n=16 patients suffering from
diabetic neuropathy experienced complete remittance in their symptoms after 12 months (Young,
Ewing & Clarke, 1988), suggesting that for most patients, neuropathic pain becomes chronic.
The range of diseases, illnesses and injuries that can result in neuropathic pain presents
certain challenges for the study of the risk factors for developing neuropathic pain. From the limited
research available it is known that individuals with chronic neuropathic pain are significantly more
likely to be female, middle age (50–64 years), divorced/separated, living in subsidized housing,
unable to work, less educated and smoke (Torrance, Smith, Bennett & Lee, 2006; Smith, Torrance,
Bennett & Lee, 2007). Another study found this population more likely to have a manual profession
and live in a rural area (Bouhassira, Lantéri-Minet, Attal, Laurent & Touboul, 2008) compared to
general population rates.
Despite the many different triggering disorders, there are common signs and symptoms
associated with neuropathy (Smith & Torrance, 2012). Clinically, neuropathic pain is characterized
by spontaneous ongoing or shooting pain which can be evoked after noxious or non-noxious stimuli.
The diagnosis of neuropathic pain is only made when the history and signs are indicative of
neuropathy in conjunction with neuroanatomically correlated pain distribution and sensory
abnormalities within the area of pain (Hansson, 2002). Questionnaires for screening and assessment
are also identified as useful tools for identifying the presence and quality of neuropathic pain (Baron,
Binder & Wasner, 2010).
A variety of pharmacological treatment options are available for the treatment and
management of neuropathic pain. First line medications include tricyclic antidepressants (Finnerup
et al., 2015), selective serotonin norepinephrine reuptake inhibitors (e.g. duloxetine, venlafaxine,
milnacipran) (Dworkin et al., 2010; Sindrup, Gram, Brøsen, Eshøj & Mogensen, 1990), and topical
7

Lidocaine, Gabapentin and Pregabalin (Freynhagen, Strojek, Griesing, Whalen, Balkenohl, 2005;
Finnerup, Otto, McQuay, Jensen, Sindrup, 2005). Second-line medications, typically used with
patients who have not responded to the first-line medications, include Tramadol and opioid
analgesics (Dworkin et al., 2010; Finnerup et al., 2015). In some cases, however (i.e. acute
neuropathic pain, neuropathic pain due to cancer) these opioid medications are the most appropriate.
An interdisciplinary approach is recommended for the management of neuropathic pain.
Components of this approach include pharmacological (i.e. tricyclic antidepressants, opioids) as well
as non-pharmacological (i.e. cognitive behavioral therapy, physical therapy, occupational therapy)
treatments. Several meta-analyses focused on treatment of neuropathic pain have been published
(Cruccu, Gronseth & Alksne, 2008; Finnerup, Otto, McQuay, Jensen & Sindrup, 2005) supporting
an approach which maximizes benefits of pharmacological treatment while minimizing harm in
terms of side-effects, comorbidities, and drug interactions.
Despite the recommendations that prescription opioids be a second-line medication for
neuropathic pain management, their use has been increasing rapidly for the past several years
(Compton & Volkow, 2006, Compton, Jones & Baldwin, 2016) and is a standard practice (Dworkin
et al., 2010; Baron, Binder & Wasner, 2010). Currently, the prescription of opioids is a common
approach for the management of neuropathic pain. When utilized to manage neuropathic pain,
opioids are prescribed using long term prescriptions for daily medication, (Dworkin et al., 2010)
often in conjunction with a lower dose narcotic to help control pain flare ups or "breakthrough" pain
(Smith, Datta & Manchikanti, 2012). Randomized clinical trials have shown satisfactory pain relief
for patients with postherpetic neuralgia (Raja, Haythornthwaite, Pappagallo, 2002; Watson, Babul,
1998) and diabetic peripheral neuropathy (Watson, Moulin, Watt-Watson, Gordon, Eisenhoffer,
2003). It is generally accepted that a reduction in pain by 30%, as measured by patient self report, is
considered clinically meaningful (Rowbotham & Peterson, 2001). One study, looking at a number
of neuropathic pain conditions found that an orally administered opioid, levorphanol, reduced pain
8

by 36% and 21% in high and low doses, respectively (Rowbotham, Twilling, Davies, Reisner,
Taylor, Mohr, 2003). These studies suggest that opioids for the management of pain can be effective
and will likely continue to be utilized for the foreseeable future.
Despite the efficacy of treating neuropathic pain in some patients, between 12% (Watson &
Babul, 1998) and 35% (Rowbotham et al., 2003; Haythornthwaite & Pappagallo, 2002) of patients
receiving opioid medications discontinued their use because of inadequate pain management.
Despite therapeutic levels of pharmacologic agents, they experienced minimal to no pain relief. This
data suggests that there remains room for improvement in the approaches for managing pain within
this population. There is also growing concern over the potential for misuse of opioids prescribed
for pain relief.
While there is little debate about short term use of opioids for acute pain, prescription of
opioids for treatment of non-cancer chronic pain, including neuropathic pain, remains controversial
and hotly debated (Fields, 2011; Compton, Jones & Baldwin, 2016). Central to this debate are two
related but different concerns; tolerance to opioid medication and addiction to opioid medication
(Vondrackova, Leyendecker, Meissner, Hopp, Szombati, Hermanns, 2008; Silverman, 2009).
Analgesic tolerance has been consistently observed in animal studies (Chang, Chen & Mao, 2007).
Analgesic tolerance and dose escalation to maintain analgesia in chronic pain patients is not
uncommon. A mild physical dependence is expected and demonstrable in patients receiving opioids
for pain management. What is unknown though, is whether the development of physical
dependence is a clinically significant problem in patients with neuropathic pain.
Related to the concerns about tolerance and dose escalation is the growing reluctance among
some providers to prescribe these medications. Their concern is that the most powerful opioid
analgesics are also those most likely to be abused and result in addiction (Ballantyne & LaForge,
2007). Unfortunately, with the rise in legitimate prescription opioid use, there has also been a
substantial increase in prescription opioid misuse and use related mortality (Chou et al., 2009).Those
9

providers in favor of a broader acceptance for the use of opioids argue that iatrogenic, or medically
induced, addiction is rare, and that it is unreasonable to withhold adequate treatment from patients
suffering from of severe pain (Edlund, Steffick, Hudson, Harris & Sullivan, 2007). While much
remains unknown, any treatment approach that can potentially lessen the reliance on opioid
analgesics while maintaining sufficient or at least comparable pain relief is worthy of further study.

Measurement of Treatment Efficacy
Challenges in the management of neuropathic pain also make outcome measurement a
formidable task. Measuring the efficacy of a new treatment can be especially difficult given the
complex, multidimensional, and subjective nature of the pain experience (Turk & Melzack, 2011).
Current research suggests that sufficient pain relief is variable depending on the pharmacological
approach and the underlying cause of neuropathic pain, however, approximately one-half of
neuropathic pain patients do not experience sufficient pain relief (Moore, Derry, Eccleston & Kalso,
2013). Sufficient pain relief is generally accepted to be at least a 30% decrease in pain (Hansson,
Lacerenza & Marchettini, 2001; Von Korff, Kolodny, Deyo & Chou, 2011), though some studies
look for as much as a 50% decrease in pain (Moore, Derry, Eccleston & Kalso, 2013). Traditionally,
the measurement of pain is done through the use of subjective pain rating scales, such as the Visual
Analogue Scale (VAS). The VAS consists of a line, usually 100 mm long, which denotes the
extremes of pain at its ends (e.g. ‘no pain’ at one end and ‘worst pain imaginable’ at the other). The
patient marks the severity of their pain at a particular point along the line. The distance of the mark
along the scale is taken as the pain score (Price, McGrath, Rafii & Buckingham, 1983). Another
common approach for measuring pain is through direct questioning about the pain (e.g. intensity,
location, descriptors, and qualities), however, this approach assumes that a reduction in pain will
translate into physical, emotional, and overall improvements. Numerous studies have shown that
changes in pain severity may have only a limited relationship to patient’s ratings of emotional and
10

physical improvement and satisfaction (Dougados, LeClaire & van der Heijde, 2002; Farrar, Young,
LaMoreaux, Werth & Poole, 2001; Dawson et al., 2002; Waddell, Nachemson & Phillips, 2000).
The traditional outcome domain of symptom reduction alone is inadequate when evaluating response
to treatments for chronic disease states and symptoms that are subjective, such as pain. As such,
although pain reduction is an important outcome, and might be a pivotal outcome for pain clinical
trials, it is important to consider other outcomes in addition to pain (Turk et al., 2003).
There is a growing body of literature highlighting the importance of additional factors,
including psychological factors, in the experience of neuropathic pain (Sullivan, Lynch & Clark,
2005; Haythornthwaite & Benrud-Larson, 2000; Daniel et al., 2008; Sullivan, Lynch, Clark,
Mankovsky & Sawynok, 2008). Severe pain causes fatigue, impaired concentration, compromised
mood, degraded sleep, and a diminished overall activity level. Thus, there is a need for a way of
assessing multiple areas of functioning and well-being in clinical research to assess the full impact of
pain treatment. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) consensus meeting made several recommendations in assessing chronic pain in clinical
trials (Turk et al., 2003). The IMMPACT group represents a variety of disciplines and includes;
anesthesiology, clinical pharmacology, internal medicine, law, neurology, nursing, oncology,
outcomes research, psychology, rheumatology, and surgery. The goal of this group was to develop
consensus reviews and recommendations for improving the design, execution, and interpretation of
clinical trials of treatments for pain (Turk et al., 2003). They suggested 4 core chronic pain outcome
domains to be measured in pain treatment research: (1) pain intensity, (2) physical functioning; (3)
emotional functioning; and (4) participant ratings of overall improvement. It is recommended that 2
or more of the 4 core chronic pain outcome domains be used to evaluate the clinical importance of
improvement or worsening for chronic pain clinical trial outcome measures. Two areas of
functioning highlighted by the IMMPACT recommendations include the assessment of emotional
functioning and an assessment of overall, or global, improvements. The recommendations
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emphasize that assessments of global functioning should evaluate diverse aspects of an individual’s
life including: the ability to carry out household chores, walking, work, travel, self-care, strength and
endurance (Turk et al., 2003). For the assessment of emotional functioning, the IMMPACT
recommendations suggest that emotional functioning could include emotional distress (Turk et al.,
2003) and/or coping through emotional approaches. With the importance of multiple forms of
measurement in pain research being highlighted, researchers are utilizing the assessment of pain
severity, physical functioning, emotional functioning, and global improvements in functioning as
unique outcomes in pain research that are important in fully assessing the multidimensional nature of
pain (Turk et al., 2003; Mikail, DuBreuil, D’Eon, 1993; De Gagne, Mikail & D’Eon, 1995; Holroyd,
Malinoski, Davis & Lipchik, 1999).
The areas outlined for the assessment of global improvements in functioning are all areas that
are commonly assessed by Health Related Quality of Life Measures (HRQoL) (Turk et al., 2003).
One meta-analysis looked at 39 articles of RCTs in which neuropathic pain and HRQoL were
measured (Haanpää et al., 2011). Of the 5 types of measures employed only two were found to have
utility in measuring changes in HRQoL in neuropathic patients. The most prominent HRQoL
measure identified was the Medical Outcomes Study 12-Item Short Form Health Survey (SF-12).
The SF-12 was first developed in 1996 as a shorter alternative to the SF-36, the most widely used
generic QoL measurement tool in the world. Initial validation of the SF-12 found that it was a
reasonable replacement for the SF-36 (Ware & Kosinski, 1996; Ware, Kosinski & Keller, 1998).
Subsequent validations have confirmed the SF-12 as a valid replacement for the Short Form-36 (SF36) with valid constructs (Gandek, Ware, Aaronson, Apolone, Bjorner, Brazier et al., 1998;
Jenkinson et al., 1997). Since that time the SF-12 has been one of the most widely used measure of
QoL among individuals from all over the world with various health issues and disease states. There
are many advantages to using the SF-12 to measure QoL. First it is very brief, taking approximately
2 minutes to complete (Wu, Hays, Kelly, Malitz & Bozzette, 1997), which can help keep completion
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rates high and limit bias due to incomplete data. Second, it has multiple administration modes
available, including paper and electronic versions, and standard (4-week) and acute (1-week) recall
versions. Research supports the use of HRQoL measures such as the SF-36 and the briefer, but
comparable revision, the SF-12, in studies measuring HRQoL
The assessment of emotional functioning includes emotional distress (Turk et al., 2003)
and/or coping through emotional approaches (Smith, Lumley & Longo, 2002). While several
measures are available for the assessment of an individual’s emotional understanding of pain, the
Pain Catastrophizing Scale (PCS) is one of the most commonly used scales with a large body of
research supporting and validating it (Sullivan, Bishop & Pivik, 1995; Keefe, Rumble, Scipio,
Giordano & Perri, 2004). The PCS is a 13-item instrument used to assess catastrophic thinking in
response to pain, and has been shown to have high internal consistency (α = 0.91) and high testretest reliability (r=0.78) (Sullivan Bishop & Pivik, 1995; Van Damme, Crombez, Bijttebeir,
Goubert & Van Houdenhove, 2002). Furthermore, the measure is easy to administer, score and it is
very short. While many measures are available that assess a variety of coping skills and include
catastrophizing, few other measures look solely at catastrophizing. For instance, the Coping Skills
Questionnaire had comparable reliability and validity to the PCS, but is a total of 72 questions,
making it too long for use in clinical settings (Robinson et al., 1997). The PCS assesses at attitudes
toward pain, specifically catastrophizing attitudes, such as; magnification of pain experience,
rumination on pain and perceived helplessness. Use of well validated measures, with a strong
research base, can allow for the identification of and change across a range of psychosocial factors.
These factors may show the efficacy of a novel treatment approach across multiple domains,
including but not limited to overall pain and allow for comparison across studies.
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Etiology of Chronic Pain
Many theories exist to explain the development and maintenance of chronic pain as well as
the resulting level of disability. A comprehensive review of all the theories lies beyond the scope of
the current literature review. The current study explored the development of disability resulting
from chronic neuropathic pain, how individuals feel about their level of disability resulting from
chronic neuropathic pain, and how feelings about this disability impact severity of pain experiences
in a neuropathic pain sample. How pain disability is maintained, and specifically, the psychological
factors associated with its maintenance, was a primary focus of this study. With these psychological
factors as the primary focus, the number of relevant theories for the development and maintenance of
chronic neuropathic pain diminishes, but still remains large.
In the chronic pain literature, a variety of theories are available to explain the development of
disability, and the role that feelings about disability may play in the maintenance of this disability.
In a review comparing the theoretical perspectives of chronic pain maintenance, Novy and
colleagues (1995) categorized pain theories into two broad groups: restrictive and comprehensive.
The restrictive theories are those that ignore plausible views of chronic pain or potential
interrelations among them as being unimportant or of secondary concern. Whereas the
comprehensive theories, as their name suggests, take into account broad perspectives on
physiological and psychological processes. These theories suggest that the limited focus of the
restrictive theories are inconsistent with the empirical literature and the multifaceted nature of
chronic pain (Novy, Nelson, Francis & Turk, 1995). Due to this inconsistency, restrictive theories,
such as mind-body dualism, sensory, information-processing, and sociogenic theories will not be
discussed in this proposal (Novy, Nelson, Francis & Turk, 1995). Comprehensive models of chronic
pain, those taking into account the biomedical considerations with attention paid to psychosocial
components of pain, have supplanted discipline-specific or one-dimensional conceptualizations of
chronic pain. Currently, multidimensional and multimodal approaches to understanding pain are
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considered state of the art and are the preferred approach (Turk & Melzack, 2011). Comprehensive
perspectives appear to represent the most up-to-date theoretical perspectives and are the most
capable of broad-based utility.
The current study examined the factors that impact the pain experience, specifically those
factors with the strongest empirical support, including: catastrophizing (Turner & Aaron 2001;
Vlaeyen & Linton 2000) and health related quality of life (Jensen, Chodroff & Dworkin, 2007).
Three of the most prominent comprehensive theories presented here include operant conditioning
theory, the biopsychosocial theory, and the fear- avoidance theory. The reasoning behind the
decision to utilize the Fear-Avoidance model to guide the current study is also discussed.
Operant Conditioning Theory. The Operant conditioning theory of chronic pain was

first described by Fordyce (1976), and it suggests that an individual experiencing pain
through noxious stimulus desires to withdraw and escape. Through this theory, chronic pain
is viewed as a subjective internal experience that may be maintained even after the initial
physical causes of pain are removed. In this model, psychological factors are treated as
secondary reactions to sensory stimulation (Turk, Dobson & Keith, 1996), and chronic pain
includes pain behaviors, namely actions, verbalizations, or facial expressions that occur in
response to pain (Fordyce, 1976). Pain-behaviors are thought to occur because the person
gains positive effects and/or avoids negative effects, and this is more important than what
initially may have caused pain (see Figure 1.). Operant conditioning theory states that what
becomes 'chronic' in chronic pain is the pain behavior, the suffering, and the disability.
Therefore, instead of looking for and treating underlying pathology, the focus of treatment is
on the pain behavior or the symptoms themselves, as these may be maintained through
reinforcement rather than physical stimuli (Fordyce, 1974). While the theory has some
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research support (Fernandez & McDowell, 1995; Gatchel, Polatin & Mayer, 1995), findings
are inconsistent, and there are many criticisms of the theory. The most relevant criticism for
the current study was that this theory focuses exclusively on motor behavior, and fails to
consider subjective, emotional, or cognitive aspects of chronic pain (Turk, 1996).
Additionally, this theory has been criticized for emphasizing pain behaviors rather than
emphasizing the pain itself (Turk, 1996). Furthermore, in neuropathic pain, the initial
physical causes of pain may not have been removed and is therefore not reinforced by motor
behaviors.

Figure 1. Examples of operant conditioning procedures in chronic pain. Pain exacerbation
contingent on activity functions as a punisher, leading to a decrease of activity levels and/or
avoidance of the specific activity on top line. Verbal or nonverbal pain expressions that elicit
attention from others increase in frequency on second line. The pain decrease that occurs during rest
reinforces its occurrence, leading to higher frequency of rest on third line. Adapted from " Operant
learning theory in pain and chronic pain rehabilitation." by R. Gatzounis, M. Schrooten, G. Crombez
& J. Vlaeyen, 2012. Operant learning theory in pain and chronic pain rehabilitation. Current Pain
and Headache Reports, 16(2), p. 119.

Biopsychosocial Theory. Another theory of neuropathic pain comes from a biopsychosocial
perspective. It was first proposed by Engel (1977) as a general approach for the identification of
factors relevant to the development of health or illness (Camic & Knight, 2004). The
biopsychosocial theory suggests a complex interaction between the biological, psychological, and
social factors involved in pain experience, health, and wellbeing (Turk, 1996b). The biopsychosocial
model takes into account the multi-dimensional nature of pain and thus recognizes the biological,
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psychological, and social components involved in both the development and maintenance of chronic
pain (see Figure 2; Gatchel, 2004).
Research into the psychological factors of pain lends support to the biopsychosocial model.
In a systematic review of the psychological factors in the development of chronic pain, Pincus and
colleagues (2002) found considerable research support indicating that distress, depressed mood, and
somatization were psychological factors involved in the development of chronic lower back pain.
Gatchel and colleagues (2007), in a comprehensive review of the biopsychosocial model, identify
research supporting the theory that emotions, such as depression, anxiety, and anger, impact the pain
experience. They go on further to say that these emotions can impact pain experience by acting as
antecedents, maintaining factors, and/or consequences. In a separate article, Gatchel (2004) reviews
how emotional states, such as prolonged stress and pain can lead to the breakdown of muscle, bone,
and neural tissue, which results in additional pain. These studies illustrate the psychological factors
that impact pain and chronic pain.
According to the biopsychosocial model, the social component of pain also plays an
important role in the development and maintenance of chronic pain. Pain can impact the role people
play within their family, within the workplace, and within their community (Gatchel & Epker, 1999).
Spouses or family members who are overly solicitous and give the pain patient significant attention
may also inadvertently reinforce the patient’s pain behaviors and their sick role (Keefe, 1992).
Additionally, social constructs such as gender, religion, and cultural can impact pain expression
(Thernstrom, 2010).
There is support for a bidirectional relationship between emotions, cognitions, and social
factors, and pain. In a review of studies to identify predictors of recovery versus continued disability
in chronic pain patients, Vlaeyen and Morley (2005) found psychosocial factors (i.e. maladaptive
attitudes and beliefs, heightened emotional reactivity, lack of social support, job dissatisfaction,
substance abuse, compensation status, prevalence of pain behaviors, and psychiatric diagnoses) were
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associated with continued disability. Furthermore, factors such as severity of injury and the physical
demands of one’s job were not found to be associated with continued disability (Gatchel & Epker,
1999; Vlaeyen & Morley, 2005).
The biopsychosocial theory does not identify specific pathways to disability, but identifies all
pathways as potentially leading to disability in chronic pain. This theory combines psychological
factors such as past experience, attention, and emotion with biological factors. Pain, theoretically,
becomes less of a signal and more of a process (Kugelmann, 1997). Therefore, there is a need to
consider the patient's daily activities in context with the meaning the patient construes from his or
her situation when assessing the pain experience (Clancy & McVicar, 1991). The complexity
inherent in this theory is one of its greatest criticisms. As a comprehensive overview of many
factors contributing to a complex problem, critics suggest that the biopsychosocial theory is too all
encompassing and functions as an 'eclectic approach' of understanding health and illness (Wood,
2012). For the purposes of looking at specific factors impacting the maintenance of chronic pain,
this approach may be too inclusive and would likely make it difficult to identify and integrate the
specific factors of focus.

Figure 2. The biopsychosocial model of chronic pain. Adapted from: "The biopsychosocial
approach to chronic pain: scientific advances and future directions", 2007, R. Gatchel, Y. Peng, M.
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Peters, P. Fuchs & D. Turk, Psychological Bulletin, 133(4), p. 581.

Fear Avoidance. The Fear-Avoidance model postulates that long term pain and

disability is increased when an individual's perceptions of the likely impact of pain lead to
safety behaviors such as escape and avoidance (Vlaeyen & Linton, 2000). Furthermore, this
model posits that some individuals are more likely than others to experience a
catastrophizing cognitive style which maintains the fear of pain and re-injury. The fearavoidance model (see Figure 3) includes the fear of movement and catastrophizing thoughts
about pain as major contributors to the pain experience.

Figure 3. Fear avoidance model of chronic pain. Adapted from “Fear avoidance and its
consequences in musculoskeletal pain: A state of the art,” J. W. Vlaeyen and S. J. Linton, 2000,
Pain, 85, p. 329.
According to the fear-avoidance model, the onset of chronic pain begins with an initial pain,
injury or disease that then interacts with an individual’s predispositional factors (i.e. affect, genetics,
personality). Following this interaction, the pain is interpreted by the individual. Those who
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interpret their pain as transitory will approach activities until their pain subsides. In contrast, those
who interpret their pain as threatening (pain catastrophizing) go on to develop pain related fear. The
latter leads to avoidance behaviors (lack of self-efficacy), and hypervigilance to bodily sensations.
These behaviors are often followed by disability, disuse, depression and an intensification of the pain
experience (Turk & Wilson, 2011). The avoidance of physical activity can be reinforcing when
individuals believe that their avoidance prevents the experience of pain. This is further maintained
by an unwillingness to engage in activities that could cause pain. The theory goes on to posit that
pain catastrophizing is also influenced by negative affectivity, helplessness and threatening illness
information (Vlaeyen & Linton, 2000).
There is a substantive body of research that supports the fear-avoidance model of chronic
pain. First, a large number of cross-sectional studies have shown that pain-related fear is indeed one
of the most potent predictors of observable physical performance and self-reported disability levels
(Tota-Faucette, Gil, Williams, Keefe & Goli, 1993; Hildebrandt, Pfingsten, Saur & Jansen, 1997).
For example, fear avoidance predicts pain intensity following treatment (i.e. high scores on
catastrophizing are associated with high pain intensity) (Samwel, Evers, Crul & Kraaimaat, 2000).
Second, the notion that pain-related fear is a precursor of disability, rather than a
consequence of it is also supported by research. A study by Klenerman and colleagues (1995), which
looked at back pain patients in a primary care setting, found indications of fear avoidance were
among the most powerful predictors of chronic disability 1 year later. Fear-avoidance is also
predictive of post treatment pain intensity. That is, negative orientation towards pain
(catastrophizing) was predictive of higher levels of pain intensity after treatment as compared to
those with a more positive orientation toward their pain (Tota-Faucette et al., 1993; Samwel, Evers,
Crul & Kraaimaat, 2000). Several studies have found that fear avoidance contributes in an important
way to disability, suffering, and health care use in patients with chronic pain, often more than pain
intensity (Vlaeyen, Kole-Snijders, Boeren & Van Eek, 1995; McCracken, 1998; Asmundson,
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Kuperos & Norton, 1997; Crombez, Vlaeyen, Heuts & Lysens, 1999). According to the fearavoidance model, patients are likely to maintain engagement in daily activities when acute pain is
perceived as non-threatening, which promotes functional recovery. In contrast, a vicious cycle may
be initiated when the pain is catastrophically misinterpreted, leading to avoidance/escape and
hypervigilance behaviors.
Despite much research support, the fear-avoidance model also has limitations. First, it does
not discuss the origin of pain related fear or the relationship between muscle disuse and reactivity.
Second, fear-avoidance doesn’t fully incorporate the role of illness information in the maintenance
or remittance of pain, specifically information and feedback about diagnostic tests provided by
medical specialists and therapists (Vlaeyen & Linton, 2000). Despite these limitations, and given
the compelling research to date, the fear-avoidance model is the most appropriate for explaining the
role of catastrophization and health related quality of life in pain maintenance. This interplay of
emotions, cognitions, and physical activity in the development of chronic pain supports the further
study of various psychosocial variables in chronic pain related research.

Catastrophizing
Historical overview of catastrophizing. The term catastrophizing has been used in the pain
field for several decades, and recurrent features in all conceptualizations of catastrophization include
attention to negative aspects of events, persistent negative thinking, and perceived inability to handle
the situation (Chaves & Brown, 1987; Spanos, Radtke-Bodorik, Ferguson & Jones, 1979).
Currently, the most common definition of pain catastrophizing is “an exaggerated negative mental
set brought to bear during actual or anticipated pain experience” (Sullivan et al., 2001). This is a
broad definition which identifies that catastrophizing involves a fixed pattern of thinking (“mental
set”) which is disproportionate in regard to the circumstances (“exaggerated”), focused on
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unpleasant aspects (“negative”) and activated when the individual confronts imaginary or actual pain
(“brought to bear”) (Sullivan et al., 2001).
The term catastrophizing was originally introduced by Albert Ellis, the founder of rationalemotional therapy (Ellis, 1962), and later adapted by Aaron Beck (Beck, 1976). In their early work,
the term catastrophizing was used to describe a maladaptive cognitive style among patients with
depressive and anxiety disorders. This cognitive style was understood as a tendency to magnify or
exaggerate possible negative aspects of future events.
Several articles were seminal in developing the framework for our current conceptualization
of catastrophizing in chronic pain (Spanos, Radtke-Bodorik, Ferguson & Jones, 1979; Rosenstiel and
Keefe, 1983; Chaves and Brown, 1987). First, Spanos and colleagues (1979) asked university
students to participate in a cold pressor procedure as a means of inducing pain in the laboratory
without causing permanent tissue damage. They interviewed the participants after the cold pressor
procedure and categorized individuals based on the content of their reported thoughts. Patients were
then assigned to one of four treatments: hypnosis plus analgesia suggestion, hypnosis alone,
suggestion alone, or no hypnosis and no suggestion. Patients then participated in the cold pressor
procedure again and reported pain. Those reporting worry, fear, and/or an inability to divert attention
away from pain were classified as catastrophizers (i.e., “I kept thinking I can’t stand this much
longer, I want to get out”) while others were classified as noncatastrophizers. The authors found that
individuals who engaged in catastrophizing thoughts reported the highest levels of pain, and showed
no response across any of treatment the conditions. In contrast, those participants who were
classified as noncatastrophizers showed significant reductions in pain reporting, some as much as a
50% reduction in pain following treatment.
A second influential study on catastrophizing was completed by Rosenstiel and Keefe
(1983), who created a 50 item questionnaire, Coping Strategies Questionnaire (CSQ), to categorize
individuals into 7 coping subscales, including a catastrophizing subscale (increasing activity level,
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diverting attention, reinterpreting pain sensations, coping self-statements, ignoring pain sensations,
praying or hoping, and catastrophizing). In one study, the CSQ was used to examine catastrophizing
in rheumatoid arthritis (RA) patients (Keefe, Brown, Wallston & Caldwell, 1989). The authors had
each participant complete the CSQ and pain scale on two separate occasions, 6 months apart. They
found that patients classified as high catastrophizers experienced greater pain intensity when
compared to those with lower catastrophization scores. Furthermore, they found that over the 6
month period, catastrophization scores remained stable. The CSQ was used in a series of studies
focusing on chronic pain patients, which consistently found that individuals who obtained high
scores on the catastrophizing scale experienced higher levels of physical and emotional distress in
relation to their pain condition when compared to participants that did not catastrophize (Keefe,
Brown, Wallston & Caldwell, 1989; Keefe et al., 1987; Crisson & Keefe, 1988).
Chaves and Brown (1987) looked at coping strategies dental patients reported using during a
stressful dental procedure. In a sample of patients undergoing dental surgery (N=75), they found
that individuals differed noticeably in the thoughts they experienced during such procedures.
Individuals who engaged in catastrophic thoughts (i.e., “I’m afraid that my pain might get worse”)
tended to magnify or exaggerate the threat value or seriousness of pain sensations. These individuals
were more likely to experience high levels of distress during their dental procedures. In the sample,
44% of patients employed cognitive strategies to minimize pain and stress, while 37% engaged in
cognitive strategies which exaggerated the fearful aspects of their experience. A small proportion,
19%, denied any cognitive activity during the procedure. The authors were able to differentiate and
label there 3 different groups; copers, catastrophizers, and deniers. The most common strategy
employed by copers was attentional diversion, while the most common strategies employed by
catastrophizers were nonimaginary negative thoughts.
Catastrophizing and chronic pain. Individuals who score higher on measures of
catastrophization consistently report higher ratings of pain intensity. This relationship is one of the
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most robust findings in the catastrophization literature. This relation has been observed in a wide
range of situations involving both acute and persistent pain, in healthy individuals, and in patients
who suffer from chronic conditions (for a review, see Sullivan et al., 2001). Catastrophizing is also
related to how people behave when confronting pain. For example, catastrophizing has been
associated with “pain behaviors”, which are the motor and verbal responses that some people
express when confronting pain (e.g. rubbing the pain area, frowning, or complaining about how
much it hurts) (Nicassio, Schoenfeld-Smith, Radojevic & Schuman, 1995). Additionally,
catastrophizing has also been linked to a heightened use of health care and increased medication use
(Bedard, Reid, McGrath & Chambers, 1997).
Catastrophizing has also been linked to higher levels of disability (Sullivan et al., 2001;
Keefe et al., 2004). This link, between catastrophizing and heightened disability, has been found in
patients with acute pain (Swinkels-Meewisse, Roelofs, Oostendorp, Verbeek & Vlaeyen, 2006) as
well as in patients with chronic pain conditions (Peters, Vlaeyen & Weber, 2005; Severeijns,
Vlaeyen, van den Hout & Weber, 2001; Turner, Jensen, Warms & Cardenas, 2002). Furthermore,
catastrophization has been found to be strongly associated with increased reports of pain and
decreased pain tolerance (Edwards, Haythornthwaite, Sullivan & Fillingim, 2004). There is
consistent evidence that individuals who catastrophize report their pain as being more intense,
express more worries and suffer more adverse consequences as a result of pain than people who do
not catastrophize (Sullivan et al., 2001; Keefe et al., 2004).
Catastrophizing is also closely related to negative emotionality. It has repeatedly been
associated with broad negative emotional responses such as depressed mood and anxiety (for a
review, see Keogh & Asmundson, 2004). Measures of catastrophizing overlap, to a large extent,
with measures of negative emotionality. Some research suggests that, after controlling for the broad
measures of negative emotionality, catastrophizing contributes minimally to the prediction of pain
(Hirsh, George, Riley & Robinson, 2007). However, other research suggests that catastrophizing is
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a unique and free standing construct that remains important despite controlling for negative
emotionality (Sullivan et al., 2001). For example, a recent clinical study showed that some pain
patients presented with either catastrophizing or depressed mood, whereas others displayed elements
of both (Linton et al., 2011). These findings indicate that it is important to separate catastrophizing
from other aspects of negative emotionality in clinical and research contexts.
Catastrophizing and response to medication. The role of catastrophizing has mainly been
studied in persistent and pathological pain situations. Few studies have looked at the role
catastrophizing plays in relation to clinical medication intervention trials of pharmacotherapies
(Mankovsky, Lynch, Clark, Sawynok & Sullivan, 2012). In the limited research to date,
investigators posit that pain catastrophizing might interfere with the effectiveness of
pharmacological interventions for pain management.
One study (N=84), looking at response to topical analgesics in patients with neuropathic
pain, found that higher scores on a measure of pain catastrophization prospectively predicted poorer
response to treatment (Mankovsky, Lynch, Clark, Sawynok & Sullivan, 2012). Using a 0-10
numerical rating scale of pain at baseline and throughout the course of treatment, the authors found
that catastrophizers presented with higher initial ratings of their pain when compared to noncatastrophizers. Additionally, they found that catastrophizers were less likely to report moderate to
substantial reductions in pain ratings over the course of treatment than non-catastrophizers
(Mankovsky et al., 2012).
Haythornthwaite and colleagues (2003) examined the efficacy of an opiate medication for
post-herpetic neuralgia (PHN), a neuropathic pain state. A total of 68 PHN patients were recruited
from community clinics and entered the study. Of those, 49 participants completed a battery of
psychological measures at study conclusion. Participant pain ratings along with questionnaire
measures of perceived interference due to pain, overall activity level, depressive symptoms, and pain
coping strategies were collected through these psychological measures. Results indicated that that
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catastrophizing at baseline predicted a higher level of pain 8 weeks later, an effect that was
independent of baseline pain and depressive symptoms.
The research into the role of psychological variables in response to pharmacological
interventions is limited. Available research suggests high levels of catastrophizing and maladaptive
coping predict poorer response to pharmacological interventions for neuropathic pain (Sullivan et al.,
2001).

Health Related Quality of Life
Historical overview of Health Related Quality of Life. Currently, Health Related Quality
of Life (HRQoL) is viewed as a multidimensional construct incorporating an individual’s evaluation
of their life with respect to three fundamental domains of functioning: (1) biological, (2)
psychological, and (3) social. A balanced measure of HRQoL captures all of these domains and
summarizes them in a single metric (WHO, 1993).
The term Quality of Life (QoL) was introduced in the middle of the last century and appeared
in the medical literature in the 1960s (Schuessler & Fisher, 1985). Since its introduction, QoL has
been defined in different ways by nearly every academic discipline. A review of QoL studies
identified over 100 definitions of QoL (Taillefer, Dupuis, Roberge & Le May, 2003). Initially, QoL
in medicine was regarded as an objective concept with a focus on independence and functioning
(e.g. activities of daily living). In the early 1980s, however, influences from social science resulted
in a greater focus on the subjective aspects of QoL (Musschenga, 1997). Quality of Life has
primarily been regarded as a multidimensional construct including at least the individual’s subjective
perception (Taillefer, Dupuis, Roberge & Le May, 2003). Some authors aim to include “all domains
of a person’s life”, while others take a more modest approach. The medical field has shown
increasing interest in a consensus on the QoL concept, however, to date, no consensus has been
reached and a large number of different conceptual models are currently used (Taillefer, Dupuis,
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Roberge & Le May, 2003). The breadth of this construct is daunting, and has been noted as an
obstacle to achieving consensus on what constitutes QoL (Koot, 2001).This lack of consistent theory
has created research problems, and makes the study of QoL very challenging.
In an attempt to narrow the QoL construct, Health Related Quality of Life (HRQoL) was
introduced. This construct mainly focuses on health specific aspects of well-being and functioning
(Koot, 2001). Qualitative and quantitative empirical data support conceptualizing HRQoL into
dimensions of physical, emotional and social functioning, and wellbeing (Sartorius et al., 1993). For
instance, a large World Health Organization research project involving adult individuals from fifteen
nations revealed that physical fitness, social integration and support, psychological stability and
ability to fulfill daily tasks seemed to contribute to HRQoL across ages, sex and cultures (Sartorius
et al., 1993, Bullinger, 2002).
Health Related Quality of Life and pain. Given the complexity and individuality of
chronic pain presentations, it is often difficult for patients to fully describe how pain has impacted
their life. Assessment of HRQoL encompasses the aspects of health and well-being valued by
patients. Specifically, measures of HRQoL can assess a patient’s physical, emotional, and cognitive
function, and their ability to participate in meaningful activities within their family, workplace, and
community.
Health Related Quality of Life is an important area of focus for pain research because it
encompasses many of the aspects of functioning that are seldom assessed in medical research. The
subjective nature of pain means that two individuals, with similar pain ratings and disability, may
have different emotional wellbeing and role functioning (Gordon, 1993). Specifically, one person
might view this pain as a serious disability, while another, with the same degree of pain, might view
it as simply an annoyance or inconvenience. While a medical focus on the physiological outcomes is
important, this is often of limited interest to the patients, in part because it doesn't result in tangible
improvements (i.e. ability to work, increased mobility). Health Related Quality of Life assessments
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are capable of measuring tangible improvements in functioning as a result of treatment, even in the
absence of any changes in pain perception.
In a review, Jensen and colleagues (2007) found 52 studies that examined the association
between neuropathic pain and HRQoL. The authors identified several common domains of HRQoL
found across most studies (physical functioning, emotional functioning, sleep, and role and social
functioning). These studies consistently found that the presence of neuropathic pain was associated
with impairments across these major domains when compared to those without neuropathic pain.
Furthermore, they found that participants who rated their pain severity as higher experienced
increased impairments in major domains of HRQoL compared to those with lower ratings of pain.
The assessment of HRQoL is an important component in identifying whether treatments that reduce
pain have additional benefits for QoL (Jensen, Chodroff & Dworkin, 2007).
One study compared two HRQoL measures (SF-36 and Nottingham Health Profile) in
patients with neuropathic pain. They found, in a sample of (N=126) participants, that those with
neuropathic pain had significantly worse scores on both measures when compared to the general
population (Meyer‐Rosberg et al., 2001). The authors found that patients who reported a high Visual
Analogue Scale score for pain reported lower global health ratings. This study further confirms the
role that pain can play on HRQoL and the utility of HRQoL measures.

N-acetyl-L-cysteine (NAC)
Research is constantly being conducted to investigate alternatives to current pharmacological
treatments for pain treatment. One particular agent that has shown promise in studies of neuropathy
is N-acetyl-L-cysteine (NAC), a parmaceutical drug and nutritional supplement, available over the
counter, with many uses in medicine. N-acetyl-L-cysteine has been used for over 30 years as a
treatment for acetaminophen overdose (Buckley, Buckley, Whyte, O'Connell & Dawson, 1999) and
carbon monoxide poisoning (Kelly, 1998). As more is understood about the actions of NAC, the
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clinical applications have also broadened. Recently, NAC has emerged as a promising treatment for
a variety of medical (Dodd et al., 2008; Adair, Knoefel & Morgan, 2001) and psychiatric disorders
(Dean, Giorlando & Berk, 2011, Deepmala et al., 2015). Data are also emerging which suggest that
NAC be effective for addiction and neuropathic pain.
A derivative of the amino acid cysteine and an antioxidant, NAC, which appears to affect
neuropathic pain by acting as a free radical scavenger has shown particular promise for treating
neuropathic pain. The use of NAC in restoring (Dean, Giorlando & Berk, 2011) and helping to
enhance glutathione concentrations (Chopra & Tiwari, 2012) is well established. Glutathione is an
antioxidant that neutralizes Reactive Oxygen Species (ROS) through direct and indirect scavenging.
Reactive Oxygen Species are chemically reactive molecules which contain oxygen and form as a
natural byproduct of the normal metabolism of oxygen (Devasagayam et al., 2004). A growing body
of research support that ROSs play an important role in cell signaling and that increased levels of
ROS can result in significant damage to cell structures (Devasagayam et al., 2004).
Reactive Oxygen Species have been shown to be involved in persistent neuropathic pain.
Kim and colleagues (2004), in a study of rat spinal nerve ligation model (SNL) of neuropathic pain,
implicated ROS in the pathology of neuropathic pain. They showed that ROS scavengers
ameliorated SNL-induced mechanical allodynia and prevented the development of neuropathic pain
in these rats. Naik and colleagues (2005) showed that NAC significantly reduced the increased
sensitivity to mechanical, thermal, and cold allodynia tests in a peripheral neuropathy model
(chronic constriction injury of sciatic nerve) in rats. Further, they noted that glutathione levels were
decreased following injury. In another study, looking at rats with induced diabetic neuropathy, the
authors found that NAC was able to reduce the physical signs of pain (decreased tail-flick latency
and decreased motor coordination) when compared to a control group (Kamboj, Vasishta & Sandhir,
2010). This research supports the role of NAC in attenuating oxidative stress associated with
neuropathic pain, and further supports the role of NAC as a potentially beneficial treatment for
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neuropathic pain patients. N-acetyl-L-cysteine, an antioxidant and precursor to glutathione
synthesis, acts by directly scavenging free radicals as well as by increasing glutathione synthesis,
results in increased cellular clearance of ROS, decreased oxidative stress, and subsequently,
decreased pain.
Orban and colleagues (2006), in a small (N=31) clinical research study, investigated the role
of NAC in decreasing pain intensity, measured by self report of pain and decreased morphine use.
They found that NAC did not decrease the pain intensity or decrease the recovery time. However,
they found that patients treated with NAC (1200 mg NAC prior to and 600 mg NAC post procedure)
showed a significant reduction in post operative morphine use (0.22 mg/kg vs. 0.47 mg/kg, p<0.05)
in the first 48 hours post-surgery compared to the control group. In this study, NAC was welltolerated with no difference in the occurrence of adverse events between the treatment groups.
Neuropathy is a common serious adverse effect of chemotherapy. In a small (N = 14)
randomized study looking at the protective effects of NAC in colon cancer patients receiving
oxaliplatin chemotherapy patients were randomized to receive NAC (N = 5) or placebo (N = 9).
Results showed a significant benefit of NAC over placebo in preventing development of oxaliplatin
induced serious sensory neuropathy (Lin et al., 2006).
Truini and colleagues (2015), conducted a double-blind, placebo controlled design, to test
NAC induced changes in quantitative sensory testing and laser-evoked potentials in healthy
volunteers. Participants (N = 10) were tested on their response to thermal-pain perceptive thresholds
and laser evoked potential measures in two separate sessions after the administration of either oral
placebo or oral NAC. Findings indicate that NAC reduced pain rating to laser stimuli but left
thermal-pain thresholds unchanged. Responses also show that NAC resulted in significantly greater
changes than placebo. Given the small sample size of these studies the results should be interpreted
cautiously, however it lends further support to the small, but growing, literature suggesting the
possibility of NAC as a favorable treatment option for neuropathic pain.
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Data are emerging which suggest that ROS play a role in the pathophysiology of addiction to
drugs of abuse as well as pain (Knackstedt et al., 2009; Cunha-Oliveira, Rego & Oliveira, 2009;
Huang et al., 2009). For instance, LaRowe and colleagues (2013) in a larger (N=111) double blind,
placebo controlled trial found no changes in cocaine use for participants randomized to receive daily
doses of 1200mg of NAC, 2400mg of NAC or placebo. However, while no effects were observed
for reducing cocaine use in cocaine dependent individuals, researchers did find that subjects who had
already achieved abstinence prior to trial entry showed longer time to relapse and lower self-reported
cravings. LaRowe and colleagues (2006), in a small (N=15) double blind, placebo controlled trial,
found that patients taking NAC reported less desire to use, less interest in response to cocaine slides
and watched cocaine slides for less time. Similar results have been found for nicotine dependence
(Knackstedt et al., 2009), marijuana dependence (Gray, Watson, Carpenter & LaRowe, 2010),
methamphetamine dependence (Mousavi, et al, 2015), pathological gambling (Grant, Kim &
Odlaug, 2007) as well as other studies of cocaine addiction (Mardikian, LaRowe, Hedden, Kalivas &
Malcolm, 2007; LaRowe, Mardikian & Malcolm, 2006).
Furthermore, NAC has shown promise in the treatment of a number of additional psychiatric
conditions, such as obsessive-compulsive disorder (Lafleur et al., 2006), schizophrenia (Berk et al.,
2008a) and bipolar disorder (Berk et al., 2008b). For a comprehensive review of clinical trials
investigating NAC in treating psychiatric and neurological conditions consult Deeplmala and
colleagues (2015).
The doses of NAC used in a range of studies, ranging from 400mg/day to 3000mg/day for 2
to 24 weeks, were well-tolerated (Gray, Watson, Carpenter & LaRowe, 2010; Knackstedt et al.,
2009; LaRowe, Mardikian & Malcolm, 2006; LaRowe et al., 2007; Mardikian et al., 2007). No
patients experienced serious adverse events, and no patients were discontinued from the studies due
to serious adverse events related to NAC.
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While research on NAC is limited, there are studies which suggest that NAC may be a
promising adjunct to standard treatments for neuropathic pain and addiction. The available research
suggests that ROS are critically involved in the maintenance of neuropathic pain and that NAC, as
an ROS scavenger may have utility in decreasing not only pain but also the potential for addiction to
the opioid medication used for pain management. The available research in support of NAC makes
it worthy of further study as an adjunct to current pain treatment regimens.
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Statement of Problem and Hypotheses
Chronic neuropathic pain is a serious health concern effecting between 1% and 8% of the
United States adult population (Dworkin et al., 2007; Torrance, Smith, Bennett & Lee, 2006;
Bouhassira, Lantéri-Minet, Attal, Laurent & Touboul, 2008). Numerous treatment options are
available for managing this pain, however, individual response to treatment is extremely variable
(Cruccu, Gronseth & Alksne, 2008). Opioid medications are one of the frequently used treatment
options for the long term management of neuropathic pain (Dworkin et al., 2010). While there are
many advantages to prescribing opioids for this patient group, including relief of pain, improved
mood, and increased functioning, long-term use of such medications is associated with increased risk
for overdose, drug interactions, medication diversion, physical dependence and addiction
(Ballantyne & LaForge, 2007). Despite the frequency of their use to treat pain, evidence on the
efficacy of long-term opioid therapy for chronic pain is limited (Chou et al., 2014) and can lead to
adverse consequences. For instance, in 2013 an estimated 1.9 million people abused or were
dependent on prescription opioid pain medications (SAMHSA, 2014). In light of this, recent
guidelines from the Centers for Disease Control (CDC) emphasize the importance of nonopioid
medications and recommend that nonopioid therapy be the preferred treatment for chronic pain
(Dowell, Haegerich & Chou, 2016). It is imperative, therefore, that we develop new strategies to aid
in the management of chronic pain thereby reducing the need for opioid medications.
Research investigating the benefits of novel uses for existing drugs and alternatives to current
pharmacological therapies is ongoing. One drug that has shown promise as a novel treatment for
chronic neuropathic pain is N-acetyl-L-cysteine (NAC). An over-the-counter supplement, NAC has
been studied as an adjunct to existing treatments for a number of psychiatric disorders including,
schizophrenia (Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz et al., 2008), bipolar disorder (Berk,
Copolov, Dean, Lu, Jeavons, Schapkaitz et al., 2008), and obsessive-compulsive disorder (Lafleur et
al., 2006). Additionally, NAC has been studied as a stand-alone treatment for several substance use
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disorders, including marijuana (Gray, Watson, Carpenter & LaRowe, 2010), nicotine (Knackstedt et
al., 2007) and cocaine (Mardikian et al., 2007) as well as for treatment of pathological gambling
(Grant, Kim & Odlaug, 2007).
The present study grew out of research on Reactive Oxygen Species (ROS); specifically, the
role of ROS in the maintenance of chronic neuropathic pain (Kwak, Lim & Baek, 2011). As a ROS
scavenger, NAC has shown promise at reducing physiological signs of neuropathic pain in
laboratory rat models (Kim et al., 2004; Kim et al., 2006). These findings prompted the present
study of NAC for patients with inadequately controlled chronic neuropathic pain.
Present study data were collected through a 4 week, open label clinical trial of NAC as an
adjuvant to opioid treatment for poorly controlled, chronic neuropathic pain. Reductions in amount
of opioids taken to relieve breakthrough pain and/or a decrease in pain severity ratings were the
primary outcome measures. The latter has often served as a proxy for improvements in other areas
impacted by chronic pain such as level of functioning and life satisfaction. However, research has
suggested that pain and functioning may not be as closely linked as previously assumed (Dougados,
LeClaire, van der Heijde, 2002; Dawson et al., 2002). Pain reduction alone does not guarantee that
physical or emotional functioning will improve (Turk & Melzack, 2011). As such, even though pain
ratings are often the primary outcome in evaluating pain treatments, it is important to consider other
outcomes to capture the various aspects of pain that can change as a result of treatment.
The current study followed the recommendation of a multidisciplinary workgroup of pain
specialists to include measures that related to pain intensity, participant ratings of overall
improvement and satisfaction with treatment, and physical and emotional functioning (Turk et al.,
2003). Self-reported use of opioid medications for break through pain, pain severity ratings
(average, highest, lowest) and measures of physical and emotional functioning were collected at
baseline, during the 4-week medication trial and at the 4-week follow-up visit.
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The present study examined the role of NAC for decreasing pain ratings (VAS scores),
reducing use of PRN opioid pain medication, and improving physical and mental health related
quality of life scores. Additionally, we examined whether appraisal of pain impacts response to
study medication. Findings must be interpreted cautiously due to the small sample size, but are
promising and support further research. Case studies of individual participants provide additional
depth to the study findings. Given the severity of the problem of chronic pain and the consequences
associated with opioid medications, the use of NAC in this population is worthy of further
exploration and remains a promising contribution in the national effort to identify suitable and well
tolerated alternatives to the reliance on opioid pain medications.

Hypotheses. The present study had 3 specific aims and evaluated the following 4 hypotheses:

Specific Aim 1: Conduct an open label pilot study of an over-the-counter pharmaceutical
drug and nutritional supplement, N-acetyl-L-cysteine (NAC) as an adjuvant to opioid treatment in
patients with inadequately controlled chronic neuropathic pain.

1.1: Examine changes from baseline in participant self-reports of pain (by Visual Analogue
Scale), doses of PRN opioid medication use and/or health related quality of life over the 4 week trial
period and at 1 month post-trial follow-up.

Hypothesis 1: Compared to baseline, study participants will report a reduction in their use of
opioid medications to manage breakthrough pain, using measures of daily morphine equivalent dose
(MED).
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Hypothesis 2: Past week VAS severity ratings for Average, Worst and Least amount of pain
will be lower over the 4-week clinical trial period than those reported at baseline.

Hypothesis 3: Upon completion of the 4 week medication trial, participants will have higher
physical and mental health related quality of life scores (as measured by the Short Form-12 survey)
than obtained at baseline.

1.2 In light of the lower than predicted sample size (which limited statistical testing of
Hypotheses 1-3), case study methods were used to examine individual participant pain rating and
PRN medication use profiles from baseline to the 4 week medication trial as well as the 1 month
post-trial follow-up visit. The purpose was to identify and characterize participant subgroups with
common patterns of response over the 10 week study period, with the goal of identifying participant
subgroups that merit further investigation.

Specific Aim 2: Examine the influence of catastrophic thinking on response to study
medication.

Hypothesis 4: After completing the 4 week medication trial, participants with a more
positive appraisal of their pain (Low catastrophizers on the pain catastrophizing scale) will have
lower Visual Analogue Scale pain ratings than participants with more negative appraisals of their
pain (High catastrophizers).

Specific Aim 3: If pilot data support future study of NAC as an adjuvant in the treatment of
chronic neuropathic pain, explore feasibility issues for a future randomized clinical trial with a focus
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on potential barriers to participant identification, study recruitment, baseline assessment measures,
retention of patients in the clinical trial and 1-month follow-up procedures.

Methods
Study Design and Overview
The present study was part of a larger project examining whether N-acetyl-L-cysteine
(NAC), an over-the-counter medication that decreases levels of oxidative stress and pain, may be a
promising adjunct to standard treatments for clinical neuropathic pain. Specifically, the present
dissertation examined the relationship between catastrophization and health related quality of life
(HRQoL) and patient response to 2400mg of NAC taken daily over a 4 week time period. Study
participants were primary care patients prescribed both a stable dose of an opioid or gabapentin as
well as “breakthrough”, or as-needed, opioid medication to treat their poorly controlled neuropathic
pain. Patients who met study criteria and provided informed consent completed a 2-week baseline
period followed by a 4 week open-label trial of NAC. Throughout this 6 week period, participants
recorded their quantity and frequency of opioid or gabapentin use, and corresponding pain intensity
ratings on a daily basis. They also noted their adherence to the prescribed NAC dosing schedule of
1,200 mg every 12 hours. Finally, they completed a follow-up assessment at 4 weeks postdiscontinuation of the NAC medication. The flow chart of study visits is outlined in Figure 4.
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Figure 4. Study Flow Chart

Study eligibility criteria. Initial study inclusion criteria were as follows: 1) between the
ages of 18 to 65; 2) scored >3 on the ID-Pain measure; 3) currently taking a stable (same dose and
dosing schedule for at least 6 months) dose of opioids for control of their neuropathic pain*; 4)
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taking short-acting opioid medication on an “as-needed” or PRN basis to control breakthrough pain;
and 5) rated their pain for the previous week as 5 or higher on the 10-point Visual Analogue Scale
(VAS). Patients were excluded from the study if they: 1) were pregnant or nursing; 2) had a serious,
unstable medical or psychiatric illness that the investigative team felt would preclude them from
safely participating in the study; 3) had an active stomach ulcer or a history of seizures or asthma; 4)
reported using non-opioid medications on an as needed or PRN basis, to control their neuropathic
pain; 5) tested positive for one or more illicit drugs by urine assay; 6) had uncontrolled
hypertension; and/or 7) were unable to comprehend spoken English.
*Note: In November, 2014, inclusion criteria were broadened to include patients taking a stable
(same dose and dosing schedule for at least 6 months) dose of either opioids or gabapentin for
control of their neuropathic pain. This expansion in the inclusion criteria for the study was
prompted by low rates of patient eligibility, caused in part by changes in primary care clinic
prescribing practices. All other study criteria remained unchanged.

Preliminary chart reviews. To estimate rates of patient recruitment into the NAC study, a
chart review was conducted with a focus on patients who had been prescribed any opioid
medication. From April, 2014 to November, 2014, primary care patient charts were reviewed,
tallying rates at which each clinical trial exclusion criterion was met by a given patient. Since one
patient could endorse more than one criterion, rates do not sum to 100%. Also, despite best efforts
to minimize duplicates, in the absence of any identifying information (which was not recorded), it is
likely that some patient records were tallied more than once. With those caveats in mind, during the
6 month review period, N = 1072 charts were examined and findings are summarized in Table 1.
The most frequent criterion leading to disqualification was absence of a neuropathic pain diagnosis
(90.6%), followed closely by the absence of a stable opioid medication (86.1%).
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Table 1.
Prevalence rates for study exclusion criteria in a chart review sample of N =1072 patients with an
opioid prescription.
Variable
Age (>65)
No diagnosis of neuropathic pain
Not prescribed a stable opioid*
Not prescribed PRN opioid
Seizures
Asthma

Prevalence rate
N (%)
207 (19.4%)
969 (90.6%)
1003 (86.1%)
747 (70.2%)
34 (3.2%)
164 (15.3%)

* Note that this review was conducted prior to the expansion in study criteria to include not just
opioid but also Gabapentin prescription for management of chronic pain.

Recruitment site and procedures. Study participants were identified through the Virginia
Commonwealth University Health System (VCUHS). This large, urban care system serves
approximately 1,500 patients with a diagnosis of neuropathic pain annually. The initial sample of
potential participants (N=275) was identified between May, 2014 and June, 2015 from 3 sources:
Ambulatory Care Clinic (n=220, 80%), Ambulatory Care Pharmacy (n=2, 0.7%), and through study
fliers posted in prominent places throughout VCUHS (n = 53, 19.3%).

Study recruitment. Potential participants were contacted and study inclusion/exclusion
criteria were discussed. If interested, those eligible proceeded with informed consent and enrolled in
the study. Figure 5 summarizes the progression from potential participant identification through
study completion.

Case identification. Several methods were used to identify potential study participants. In
the ambulatory care clinic, 2 approaches were used. First, the research assistant (RA) would review
medical records of patients scheduled to be seen in primary care on a given day, to identify those
who might meet the aforementioned study inclusion/exclusion criteria. Second, primary care
physicians were informed about the study on an ongoing basis, emphasizing eligibility criteria, and
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encouraging practitioners to refer potentially eligible patients to a member of the research team. In
addition, flyers describing the study were posted in strategic places and circulated around the
hospital, with information about how to contact the PI or member(s) of the research team about the
study. Lastly, for 3 months (November, 2014- January 2015), potential participants were identified
through an ancillary study taking place in the VCU Ambulatory Care Pharmacy where they were
informed about the study.
Of the N = 275 persons identified, N = 88 were duplicates, yielding a sample of N = 187
unique potential participants. Of these, N = 20 could not be reached by phone to schedule an
appointment; N = 27 missed or cancelled one or more appointments; and N = 35 were missed due to
limitations in RA and other staff member time and availability (see Figure 2).

Initial contact. Next, a member of the research team met with potential participants,
typically before or after a scheduled medical appointment, to talk about the study. Patients who
expressed interest were escorted to a more private room or place in the waiting areas to discuss study
participation.
Of the N = 105 individuals contacted by the research team, N = 23 declined screening. The
remaining N = 82 were provided with inclusion/exclusion criteria by study personnel and of these,
N=50 indicated they did not meet study criteria. Specific reasons included: over 65 years of age
(N=1), ID-Pain ratings < 3 (N=2), not prescribed a stable opioid medication or Gabapentin (N=17),
not prescribed an "as needed" or PRN opioid medication (N=16), reported a sub-threshold (<5)
average pain score for the previous week (N=4), had a history of seizures (N=1) or asthma (N=8), or
reported illicit substance use (N=1).

Informed consent. The remaining N = 32 patients who met study criteria were invited to
participate in the study. Of these, N = 4 chose not to participate in the study. The remaining 28
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provided informed consent and proceeded to baseline assessment. This study was reviewed and
approved by the VCU Institutional Review Board (IRB) with an Investigational New Drug (IND)
approval from the Food and Drug Administration.

Participants
Participants were N=28 individuals with chronic, non-cancer, neuropathic pain who were
identified through the VCU health system, met study criteria, and provided informed consent. All
were receiving medical care and long-term medication management of chronic pain through the
VCU Primary Care clinics. Of these, N = 17 did not complete the baseline period for the following
reasons: lost to follow up despite repeated attempts to contact (N = 7), no longer meeting study
inclusion criteria (e.g. no longer taking PRN opioid, no longer taking stable opioid or gabapentin,
evidence of illicit drug use) (N = 5), study physician or primary care physician recommendation that
they not participate (N = 2), or participant decision to discontinue study participation (N = 3). The
remaining N = 11 (39%) proceeded with the open-label NAC trial and were instructed to take 2400
mg NAC daily for 4 weeks. Medication was dispensed weekly during the active treatment phase of
the protocol. One participant was subsequently withdrawn from the study because of an allergic
reaction during week 1 of the active phase. The remaining N = 10 completed the 4-week trial and
the one month follow-up assessment. The final sample was predominantly female (63.6%); Black
(72.7%); never married (81.8%); with a mean age of 49.9 years (SD= 7.1, Range = 18-64 years of
age).
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CONSORT diagram for study recruitment

Cases screened
(n =275)

Cases were identified through:
 Chart review 78.2% (n= 215)
 Provider referral 1.8% (n= 5)
 Study flyer 19.3% (n= 53)
 Ancillary Study 0.7% (n= 2)
Duplicate cases
(n =88)

Unique patients
(n =187)

Patients not approached (n=82):
 Unable to contact (n=20)
 Missed or canceled medical
appointment (n=27)
 Research staff unavailable
(n=35)

Patients contacted
(n =105)

Declined screening (n=23)

Excluded (n=50):
 Age (>65): n=1
 <3 on ID-Pain: n=2
 Not prescribed stable opioid or Gabapentin: n=17
 Not prescribed PRN: n=16
 Sub-threshold average pain rating (<5): n= 4
 Seizures: n=1
 Asthma: n=8
 Other: n=1

Screened for eligibility
(n=82)

Met study criteria
(n=32)

Provided informed
consent (n=28)

Declined enrollment (n=4)
Uninterested: n=4

Participants withdrawn before initiating NAC (n=17):
 Lost to follow up: n=7
 No longer met study inclusion criteria: n=5
 Physician recommended withdrawal: n=2
 Participant initiated withdrawal: n=3

Completed baseline and
started NAC (n=11)

Participated in 4-week
open label trial (n=11)

Discontinued due to allergic reaction (n=1)

Completed 4 week
follow up assessment
(n=10)

Figure 5. CONSORT diagram
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Procedure
Preliminary screening for study eligibility. When first contacted, either by phone or in
person, patients were verbally prescreened using several questions about primary inclusion and
exclusion criteria. To confirm eligibility, they were routinely asked to rate their pain experience
(past week) on a scale of 1-10, affirm use of "as needed" opioid pain medication, and score > 3 on
ID-Pain scale. Individuals who remained eligible and expressed interest in study participation
proceeded with informed consent. This occurred at the initial visit or an appointment was set to
complete these procedures.

Informed consent and study enrollment. Patients who met study criteria and had interest
in study participation were given a copy of the Research Consent Form and proceeded with
screening assessment. The RA reviewed the document with them, explaining the schedule of 8
study visits over the 10 week time period (see Figure 6), they included: Screening Visit, two
Baseline Visits, four weeks of treatment with a visit at the end of each week, and a Follow-Up Visit
four weeks after completing the NAC treatment phase. The RA explained that these survey questions
would focus on: pain, mood, stress, general functioning, demographics. Compensation for study
participation was also reviewed, and the RA informed them that urine tests would be conducted to
assess for illicit drug use, and, in women, pregnancy.
The RA reviewed potential risks and discomforts of study participation, alternatives to
participation, and an explanation of the voluntary nature of participation. Further, the RA informed
participants that all data was confidential and that if published or presented, that the findings would
not contain any identifying information. For patients who were interested in participating in the
study and who meet the eligibility criteria, the RA obtained written informed consent for study
participation. Participants who were no longer interested in participating were thanked for their time
and not enrolled in the study.
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Initial assessment. Upon completing informed consent, the following information was
collected; 1) demographics; 2) medical history; 3) a Concomitant Medication inventory (including
questions about prescription, non-prescription, and medical/nutritional supplement use); 4) a urine
drug test (testing for cocaine, cannabis (THC), and amphetamines); and for women of childbearing
age, 5) a urine pregnancy test.
After affirming participant eligibility, they received the Daily Monitoring Form and the RA
explained it was used for tracking both stable and PRN pain medications (including Gabapentin after
inclusion criteria were amended). They were instructed in how to record dose taken, time each dose
was taken, and Average and Worst VAS pain ratings at the time medications were taken. Upon
completing initial assessment, participants were given an appointment for a follow up in 1 week and
compensated with a $5 gift card for their time and effort. See Figure 6 for the measures collected at
each study appointment. If the participant was found to no longer be eligible (e.g. they are pregnant,
using illicit substances) they were informed of this, thanked for their time, provided with study
compensation and withdrawn from the study.
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Baseline
Week 1
Baseline
Week 2
Treatment
Week 1
Treatment
Week 2
Treatment
Week 3
Treatment
Week 4
4 week
follow up

X

X

X

X

X

X

X

X

X
X

Compensation

NAC Pill Count

Concomitant Medication

Mood (PHQ-9)

Stress (PSS)

Disability (PDI)

X

Catastrophizing (PCS)

VAS

X

X

SF-12 (HRQoL)

Urine Drug Screen,
Pregnancy Test
Daily Monitoring Form

Physical Examination

Demographics
Intervention

Baseline

Screening

$5

X

X

X

$10
$10

X

X

X

X

X

X

X

X

X

X

$30

X

X

X

X

X

X

X

$30

X

X

X

X

X

X

X

$30

X

X

X

X

X

X

X

X

X

$50

X

X

X

X

X

X

X

X

$10*

* a bonus gift card of $25 was also given at this visit if the participant completed all study visits.
Figure 6. Study procedures and measures by study visit.
Baseline period. Following study enrollment and initial assessment, participants returned
for two baseline appointments.
Baseline 1. At Baseline 1, participants Daily Monitoring Forms with medication use and
pain ratings were reviewed and new forms were provided. Any questions about the study were
answered and the next appointment was made for approximately 1 week later. Participants were also
thanked for their continued participation and compensated with a $10 gift card for their time and
effort.
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Baseline 2.
Physical Examination. At baseline 2, the participant completed a physical examination with
the study physician. In addition to an evaluation of general appearance, review of body systems, and
assessment of vital signs, the study physician assessed for any medical conditions that would
preclude study participation. If the participant was approved for continued study participation,
he/she proceeded with Baseline 2 assessment measures.
If participant was not approved for medical reasons, this was explained to them. After
answering any questions they were thanked for their time, provided compensation for the visit and
withdrawn from the study.
Medication. The treatment consisted of the addition of NAC to the participants existing
medication regimen. The treatment adjuvant, NAC, was provided as 600-mg capsules. The active
treatment period lasted for four weeks. Each week, participants were provided a one week supply of
NAC (+/- two days) and written and verbal instructions on how to appropriately take the study
medication. Participants were instructed to take two, 600 mg capsules, twice daily (in the morning
and in the evening). They were told if they missed a dose of the study medication, they should either
take the dose (if it is more than six hours before their next scheduled dose) or skip the dose of NAC
(if it was six hours or less until their next dose). Participants were also reminded to note all such
events on their Daily Monitoring Forms. They were also instructed to return their NAC pill bottles
and any remaining study medication at each subsequent study appointment and they were told that
pill counts would be conducted to confirm their reported medication usage.

The study medication, NAC, is an herbal dietary supplement regulated as a food by
the FDA. Dietary supplements containing NAC are widely available in health food stores
and on the Internet. FDA regulations concerning the manufacture of these products are
different than those for prescription drugs, but all domestic and foreign companies that
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manufacture dietary supplements for distribution in the United States, must comply with the
Dietary Supplement Current Good Manufacturing Practices (cGMPS) for quality control
(http://www.fda.gov/Food/DietarySupplements/default.htm). The NAC medication used in
the current study was provided by General Nutrition Centers (GNC) in 600mg capsules.
Concentration and bioavailability of the NAC medication was not established for the current
study.
Baseline 2 measures. After completion of the physical examination, the following were
completed: 1) pregnancy test; 2) urine drug test; 3) Visual Analogue Scale (VAS); 4) Pain
Catastrophizing Scale (PCS); 5) Short Form Health Survey-12 (SF-12); 6) Pain Disability Index
(PDI); 7) Patient Health Questionnaire (PHQ-9); 8) Perceived Stress Scale (PSS); 9) Concomitant
Medication inventory. Additionally, completed Daily Monitoring Forms were reviewed and
collected from the participant. Blank Daily Monitoring Forms were provided. A one week supply
(+/- 2 days) of the study medication was provided and a follow up visit was scheduled for the
following week. Participants were also thanked for their continued participation and compensated
with a $10 gift card for their time and effort.
Treatment Period. At the conclusion of baseline 2, participants entered the active treatment
period. The active treatment period lasted for four weeks. Participants followed up with in-person
clinic appointments weekly for the four weeks of active treatment and were provided with a one
week supply (+/- 2 days) of the study medication.
Treatment 1. The following measures were completed:1) VAS; 2) PDI; 3) PHQ-9; 4) PSS;
5) urine drug screen; 6) pregnancy test; 7) Adverse event assessment; 8) medication compliance
assessment; and 9) Concomitant Medication inventory. Additionally, completed Daily Monitoring
Forms were reviewed and collected from the participant. Blank Daily Monitoring Forms were
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provided. At the completion of this appointment, a one-week supply (+/- two days) of study
medication was provided and a follow up visit was scheduled for the following week. Participants
were also thanked for their continued participation and compensated with a $30 gift card for their
time and effort.

Treatment 2-3. Identical measures were collected, and procedures followed, for Treatment 2
and Treatment 3, as were followed in Treatment #1 visit.

Treatment 4. This appointment marked the conclusion of the active treatment period. At
this appointment, all the measures collected at the Treatment 1-3 visits were collected (VAS, PDI,
PHQ-9, PSS). In addition to these measures the following measures were collected; 1) PCS; 2) SF12. Completed Daily Monitoring Forms were reviewed and collected from the participant. At the
conclusion of this appointment a 4 week supply of blank Daily Monitoring Forms were provided and
participants were asked to continue tracking their stable and PRN pain medications (including
Gabapentin) that they were currently taking, dose taken each day, time each dose was taken, and
pain ratings prior to taking medication. Finally, a follow up visit was scheduled for approximately 4
weeks after Treatment #4. Participants were thanked for their continued participation and
compensated with a $50 gift card for their time and effort. Urine drug screens and pregnancy tests
were no longer collected at this appointment.

4-Week Follow-up. Participants returned for an in-person follow up visit approximately 4
weeks after they completed taking the study medication. At this final study visit, participants
completed 1) VAS; 2) PCS; 3) SF-12; 4) PDI; 5) PHQ-9; 6) PSS, and 7) Concomitant Medication
inventory. Participants returned their Daily Monitoring Forms and they were reviewed with the RA
for errors. Participants were also thanked for their continued participation and compensated with a
49

$10 gift card for their time and effort. They were provided with an additional bonus gift card for $25
if they attended all study appointments. This appointment marked the conclusion of their study
participation and no further visits were scheduled.

Compensation. Participants were compensated for their time and effort. They received $5
for completing the Screening Visit, $10 for completing Baseline week 1, $10 for completing
Baseline week 2, $30 for completing each of the first three, weekly Treatment Visits, and $50 for
completing the final weekly Treatment Visit. At the final visit, the 4-Week Follow-Up, participants
received a $10 gift card and an additional $25 if they have attended each of their study visits. Thus,
the potential maximum compensation for this study was $200.

Reminder Calls and Missed Appointments. The business day prior to each scheduled study
appointment the RA would call to remind the participant about the appointment date, time, and
location. If the participant was unable to make the appointment it was rescheduled. If a participant
missed a scheduled appointment the RA would attempt to reach the participant by phone to
reschedule the appointment. A discrete voicemail message was left requesting a return phone call if
the participant was unavailable. Participants who could not be reached were called every week
throughout the study or until contact had been established. The RA called the participants’ back-up
contacts if contact could not be established with the participant. Participants were withdrawn from
the study if contact could not be reestablished or, if when contact was reestablished, the participant
requested to be withdrawn from the study. The same procedures were followed for all study
appointments and documented in the participants' study chart.

Research Personnel. Research personnel included graduate and undergraduate research
assistants. All research personnel completed the CITI online training in human subjects’ protection.
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In addition, Drs. Svikis and Dillon conducted a variety of protocol-specific (e.g., participant
recruitment, forms administration, standard operating procedures, emergency procedures, adverse
event reporting procedures, etc), and intervention-specific training activities prior to study start and
during the course of the study. The trainings included both didactic and hands-on/experiential
learning activities. Additional booster trainings were conducted with research staff throughout the
course of the study.

Measures and Participant Information
Demographics. Basic demographic information was collected at baseline using an RA
administered self-report questionnaire. Questionnaire items included: age; race (Caucasian, African
American, Hispanic, Other), years of education, marital status (single/married), employment status
(full time/part time), receipt of disability. This information was collected at study enrollment.

Medical and Medication History. A brief medical history was obtained with particular
focus on duration of pain, as well as comorbid psychological and medical diagnoses. Information
about pain medications type, dosage and frequency of use for both stable dose and “break through”
drugs as well as concomitant medications (e.g., prescription, non-prescription and
medical/nutritional supplements). This information was reported by participants at study enrollment
and confirmed through chart review after completion of the study visit.

Visual Analogue Scale (VAS) of Pain Severity. Visual analogue scales are a measurement
instrument for subjective characteristics or attitudes that cannot be directly measured (i.e. cravings,
anxiety) and is regularly used to assess pain (Wewers & Lowe, 1990). The VAS uses a 100 mm
long horizontal line to demarcate the possible range of pain ratings from “0” no pain at all to “100”
worst pain imaginable at the other. Participants are asked to characterize pain severity by making a
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vertical line crossing the horizontal line at a particular point along the line. The measurement
continuum is also believed to provide greater sensitivity than a numerical scale (Flaherty, 1996).
Test–retest reliability of the VAS for pain has been reported to be high for the VAS (r = 0.73-0.82)
(Good et al., 2001). Participants completed the Visual Analogue Scale (VAS) at each study visit.
Participants rated their Average, Worst, and Least pain for the previous week on a 100mm
line. The VAS rating was converted into a score ranging from 0 to 100.

Pain Catastrophizing Scale (PCS). The Pain Catastrophizing Scale (PCS) (Sullivan et al.,
1995) is used to assess catastrophic thinking in response to pain. The 13 item questionnaire asks
participants to rate frequency of specific pain-related thoughts and feelings using a 5-point Likert
scale (0, not at all to 4, all the time). The PCS has been shown to have high internal consistency (α =
0.91) and high test-retest reliability (r=0.78) (Sullivan Bishop & Pivik, 1995; Van Damme,
Crombez, Bijttebeir, Goubert & Van Houdenhove, 2002). This information was collected at three
time points; Baseline #2, Treatment #4 and 4-Week Follow-up.
The total PCS score (0-52) of participants were used to identify a median of 25.5 (SD =
10.70). Participants were divided into Low catastrophizers or High catastrophizers using the median
split of the PCS total scores. Additionally, three sub scores were calculated from the PCS (e.g.
magnification, rumination, and helplessness) using criteria established by Sullivan and colleagues
(1998). For the subscales, a sum of the response to a subset of responses were used. Rumination
was calculated using responses to questions 8, 9, 10 and 11. Magnification was calculated using
response to questions 6, 7 and 13. Helplessness was calculated using responses to questions 1, 2, 3,
4, 5 and 12.

Short Form-12 Health Survey Questionnaire (SF-12). The SF-12 is a brief version of the
Short Form-36 (SF-36) health-related survey instrument (Ware, Kosinski & Keller, 1995, 1996).
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The SF-12 requires 2-3 minutes to complete (Ware & Gandek, 1998) and measures of patient’s
physical (PCS) and mental (MCS) functioning. Both scales have good internal consistency (PCS α =
0.82; MCS α = 0.85). This information was collected at three time points; Baseline #2, Treatment #4
and 4-Week Follow-up.
The present study examined the scores obtained from the Physical Component Summary
(PCS) scale and the Mental Component Summary (MCS) scale. Criteria for calculation of the PCS
and MCS were obtained from A guide to the integration of certified Short Form survey scoring and
data quality evaluation capabilities provided by QualityMetric Incorporated (Maruish & DeRosa,
2009).

ID-Pain Questionnaire. The ID-Pain questionnaire is a 6 item screener for neuropathic pain
(Portenoy, 2006). The ID- Pain has been used to assess neuropathic pain general populations
(Ohayon & Stingl, 2012), primary care settings (Haanpää, 2009), as well as for neuropathic pain
within specific population, such as osteoarthritis (Ohtori et al., 2012) and breast cancer (ReyesGibby, Morrow, Bennett, Jensen & Shete, 2010). The measures requires 1-2 minutes to complete
and is scored by adding the responses. All “Yes” answer to questions 1–5 are scored as 1, while a
“yes” answer to question 6 is scored as −1. A total score of > 3 was established as the minimum cut
off for identifying neuropathic pain (Portenoy, 2006). In the initial scale development study
conducted by Portney (2006), the ID-Pain items were found to accurately predict diagnoses of
neuropathic pain determined by pain specialists, with concordance c indices in the studies of 0.73
and 0.69. The ID-Pain questionnaire is highly correlated with the Douleur Neuropathique 4 (DN4)
(r = 0.8), another measure of neuropathic pain (Padua et al., 2013). The ID-Pain showed sensitivity
78% and specificity 74% (Padua et al., 2013). Participants with a score lower than three were
withdrawn from the study. This information was collected at study enrollment.
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Patient Health Questionnaire – 9 (PHQ-9). The nine-item PHQ-9 is a self-report measure
designed to measure depressive symptoms (Kroenke, Spitzer & Williams, 2001). The PHQ-9 has
been used for both diagnostic and treatment monitoring purposes. The PHQ-9 assesses DSM-IV
diagnostic symptoms of depression with Likert-type ratings on a “0” (not at all) to “3” (nearly every
day) scale (Range = 0-27). Psychometrics have been assessed in a number of settings, including,
primary care (Spitzer, Kroenke & Williams, 1999), ob/gyn (Spitzer et al., 2000), and in a general,
non-medical population (Martin et al., 2006). The PHQ-9 has demonstrated high internal
reliabilities (α = .89 and .86) and forty-eight hour test-retest reliability (α = .84) (Kroenke, Spitzer &
Williams, 2001). The PHQ can be meaningfully applied as a diagnostic proxy for depression (score
> or = 10 has 88% sensitivity and 88% specificity), and provides a continuous measure of severity
(Total Score). The PHQ – 9 has been found to be a practical and responsive tool among both men
and women (Löwe, Schenkel & Carney-Doebeling, 2006). This information was collected at every
study visit.

Daily Monitoring. Daily Monitoring Forms were used to assess pain medication use. The
Daily Monitoring Form is a paper-and-pencil record that was completed by participants daily.
Participants recorded both their stable and PRN pain medications (including Gabapentin after
inclusion criteria were amended) that they were currently taking, dose taken each day, time each
dose was taken, pain ratings (Average and Worst) prior to taking medication. During the treatment
period participants were also asked to record when they took the NAC medication on the Daily
Monitoring Form. Participants returned the completed Daily Monitoring Forms at each subsequent
study appointment. Further instructions for filling out the Daily Monitoring Form were provided as
needed. This information was collected at every study visit from Baseline #1 through the 4-Week
Follow-up.
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Information on opioid medication, collected on the Daily Monitoring Form, was converted
into morphine equivalents dose (MED). The potency of one opioid medication is not necessarily the
same as another and the MED was calculated using a formula that allows the standardization of
opioid pain medication. A calculator was used to convert prescribed opioid medications (i.e.
Tramadol, oxycodone, Fentanyl) into MED. For the purposes of this study, MED was calculated by
following the criteria outlined in McPherson (2010). Specifically, the online calculator provided by
the Washington State Agency Medical Directors’ Group was used for such calculations
(http://www.agencymeddirectors.wa.gov/).

Study Phase. The data were divided into three discrete time points, or phases, because of the
possible changes in slope due to the addition or discontinuation of the study medication. The PreNAC Phase consisted of Baseline 1, and Baseline 2; the NAC Phase consisted of Treatment 1
through Treatment 4; and the Post-NAC Phase consisted of the 4-Week Follow Up.

Data Management. Data were entered continuously throughout the study by RA’s. Data
were reviewed for missing, illogical, out of range, and inconsistent values; accuracy of key variables
such as gender, age, race, medication adherence, pain ratings. Any problems that were encountered
that needed correction and clarification were addressed by the project coordinator with the RA's.
Participant confidentiality was maintained through a numbered reference system with
participants names appearing on the “key”, which was kept by the project coordinator. Data were
entered into a REDCap database, which uses a MySQL database via a secure web interface. Access
to the study's data in REDCap was restricted to the members of the study team by username and
password.
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Data Analysis Plan
Demographics. Statistical analyses were performed using SPSS v.23.0 (SPSS, Chicago, IL).
The data set was prepared and assessed for any outliers or missing data. Descriptive analyses to
describe demographic characteristics (e.g., age, race, education) were calculated.
Hypotheses. The hypothesized relationships between the study medication and reductions in
opioid use was examined (Hypothesis 1). A mixed linear model was fit with Time, NAC (Yes or
No), and MED (Daily reported morphine equivalent doses). The model included an effect for
day/time (1 to the maximum reported days for each subject), NAC use on the day (Yes or No) and
the interaction between day/time and NAC use. An AR(1) variance-covariance matrix was used to
model the within subject correlation. Nonsignificant interaction terms were removed from the
model. Additionally, a mixed linear model was fit to the data to examine the impact of time and
NAC use on pain ratings (Average, Worst) for each day.
A hypothesized relationship between the study medication and reductions in global
assessments of pain was examined (Hypothesis 2). A repeated measures analysis of variance was
conducted with global pain ratings (VAS) as the DV and the repeated factor of time (Baseline #1
[week 1], Baseline #2 [week 2], Treatment Period #1 (week 3), Treatment Period #2 (week, 4),
Treatment Period #3 (week 5), Treatment Period #4 (week 6), and 4-week follow up (week 10).
Additionally, a repeated measures analysis of variance was conducted with global pain ratings
(VAS) as the DV and the repeated factor of phase of study (Pre-NAC [Baseline #1, Baseline #2],
NAC [Treatment Period #1, Treatment Period #2, Treatment Period #3, Treatment Period #4], PostNAC [4-Week Follow Up]).
The hypothesized relationship between the study medication and improvements in HRQoL
was examined (Hypothesis 3). Paired samples t-tests were performed to compare HRQoL subscores
across three time points (Baseline 2, Treatment period 4, and 4-Week Follow Up). Paired-samples ttests were run for both the MCS and PCS scores derived from the SF-12 across the three time points.
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A hypothesized relationships between appraisal of pain and global pain experience was
examined (Hypothesis 4). A mixed between-within subjects analysis of variance was conducted
with appraisal of pain (Low catastrophizer, High catastrophizer) as the between-subjects independent
variable (IV). The dependent variable (DV) was the global pain rating as measured through the
Visual Analogue Scale (VAS) score measured at each time period (Baseline #2 [week 2], Treatment
#4 [week 6], and 4-Week Follow Up [week 10]) across three separate ratings; Average, Worst, and
Least pain for the previous week. The within-subjects factor was time (Baseline #2 [week 2],
Treatment #4 [week 6], and 4-Week Follow Up [week 10]).

Results
Data Analysis
Outliers and Tests of Normality. Prior to any analysis, the data was examined for
normality of distribution and for the presence of outliers. Descriptive statistics (mean, standard
deviation, median) were generated for the demographic variables collected at baseline. Given that
this is an open label study, without a control group, each participant acted as their own control.
Frequency distributions of continuous variables were examined for evidence of non-normality and
outliers. If the data contained outliers and there was a meaningful rationale to remove them (e.g.,
outliers were not expected), they were coded as missing. If by removing outliers the data were
normal, no further changes were made to the variable. In one participant, at Treatment 4
appointment, an obvious error was made in identifying the least, average, and highest pain scales at
one visit (e.g. the rankings were in the single digits and the least pain exceeded the highest and
average). In this case a mean substitution for the Average, Least, and Worst pain ratings were used.
Initial examination of the data showed that while the sample was slightly skewed and
kurtotic, the values were not above 1.5 on either statistic. Variables were normally distributed and
within expected ranges.
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Characteristics of the Sample
Demographics: Demographic characteristics for participants who initiated NAC treatment
(N=11), those who did not (N=17) and the total sample (N=28) are shown in Table 2. Participants
who initiated NAC had an average age of 49.9 years (SD= 7.1, 18-64 years old). They were almost
two thirds female (63.6%) and they identified themselves either as Black (72.7%) or Caucasian
(27.3%). Participants reported a mean of 12.4 years formal education (SD = 1.2, range 10-14 years)
and most were single (never married) (81.8%) at the time of study participation. Participants who
did not initiate NAC were similar on age, education, marital status, and receipt of disability.
Participants who did not initiate NAC were nearly twice as likely to be male (70.6%) compared to
those who did initiate NAC (36.4%). They were also less likely to have a disability case pending
(35.4% vs. 45.5%) or be African American (64.7% vs. 72.7%).
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Table 2.
Participant Characteristics: Initiated NAC (n =11) and Enrolled (N=28)
Initiated NAC Did not
treatment
initiate NAC
(N=11)
treatment
(N=17)

Age (years)
Gender
Female
Male
Education (years)
Marital Status
Married/cohabitating
Single/divorced/widowed
Separated
Ethnicity
Caucasian
African American
Disability
Disability case pending
Employed (part or full time)

Total Sample
(N=28)

Total (%) or
M (SD)
49.9 (7.1)

Total (%) or
M (SD)
47.7 (8.5)

Total (%) or
M (SD)
48.3 (7.9)

7 (63.6%)
4 (36.4%)
12.4 (1.2)

5 (29.4%)
12 (70.6%)
12.1 (2.0)

12 (42.9%)
16 (57.1%)
12.2 (1.8)

1 (9.1%)
9 (81.8%)
1 (9.1%)

2 (11.8%)
14 (82.4%)
1 (5.9%)

3 (10.7%)
23 (82.1%)
2 (7.1%)

3 (27.3%)
8 (72.7%)
4 (36.4%)
5 (45.5%)
2 (18.2%)

6 (35.3%)
11 (64.7%)
6 (35.4%)
6 (35.4%)
5 (29.4%)

9 (32.1%)
19 (67.9%)
10 (35.7%)
11 (39.3%)
7 (25.0%)

Neuropathic Pain. Neuropathic pain symptoms for participants who initiated NAC
treatment, those who did not and the total sample are presented below (Table 3). A cut off score of
>3 was established by Portenoy (2006) to identify neuropathic pain and was used as an inclusion
criterion for the current study. Participants who initiated NAC tended to report higher rates than
those who did not initiate NAC of their pain feeling "like pins and needles" (100% vs. 94.4%), and
"like electric shocks" (81.2% vs. 72.2%). Participants who did not initiate NAC reported higher
rates of their pain feeling like "burning" (83.3% vs. 72.7%), "numb" (88.9% vs. 63.6%), and "worse
with the touch of clothing or bed sheets" 44.4% vs. 27.3%). Participants who did not initiate NAC
also reported more frequently that pain was "limited to (their) joints" (11.1% vs. 0%).
Participants ID-PAIN responses are presented below (Table 4). Participants who initiated
NAC tended to endorse fewer ID-PAIN responses than those who did not initiate NAC; 3 ID-PAIN
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responses (63.3% vs. 47.1%), 4 ID-PAIN responses (27.3% vs. 29.4%), and 5 ID-PAIN responses
(9.1% vs. 23.5%).

Table 3.
ID-Pain responses

ID-PAIN Question
Did the pain feel like pins and
needles?
Did the pain feel like burning?
Did the pain feel numb?
Did the pain feel like electric
shocks?
Is the pain worse with the
touch of clothing or bed
sheets?
Is the pain limited to your
joints?
Table 4.

Initiated NAC Did not
(n=11)
initiate NAC
(N=17)
Yes
Yes
100%
94.4%

Whole sample
(n=28)

72.7%
63.6%
81.2%

83.3%
88.9%
72.2%

78.6%
78.6%
78.6%

27.3%

44.4%

39.3%

0%

11.1%

7.1%

Yes
96.4%

Percentage of ID-PAIN responses endorsed
Number of ID-PAIN
responses endorsed
3 responses endorsed
4 responses endorsed
5 responses endorsed

Initiated NAC Did not
(n=11)
initiate NAC
(N=17)
63.6%
47.1%
27.3%
29.4%
9.1%
23.5%

Whole sample
(n=28)
53.6%
28.6%
17.9%

Medical and Pain Diagnoses. Participants reported their current medical and pain
diagnoses at study enrollment and these were confirmed through chart review. There was no
significant difference in number of medical diagnoses for participants who initiated NAC (M=11.18,
SD=4.62) and participants who did not initiate NAC (M=8.18, SD=3.64; t (26) = -1.92, p = .066).
Similarly, there was no significant difference in scores for participants who initiated NAC (M=2.73,
SD=1.10) and participants who did not initiate NAC (M=2.59, SD=1.23; t (26) = -.30, p = .763) on
60

number of pain diagnoses. The most common pain diagnoses, assessed at study enrollment, include:
chronic pain diagnosis with an unspecified etiology (e.g. "chronic pain", "knee pain", "shoulder
pain", "back pain", "hip pain"), diabetic neuropathy, fibromyalgia, unspecified neuropathy (e.g.
"neuropathy", "polyneuropathy"), arthritis, and gout.

Pain Medications. Participant reports of pain medications they were prescribed at study
enrollment are presented in Table 5. Most frequently prescribed medications for both those who
initiated NAC and those who did not were Oxycodone and Tramadol. The percentage of participants
who were prescribed Oxycodone (54.5% vs. 35.3%) and Gabapentin (81.8% vs. 41.2%) at baseline
was higher than the percentage of participants who did not initiate the 4 week trial. However,
participants who initiated NAC were prescribed Hydrocodone (9.1% vs.23.5%), Tramadol (36.4%
vs. 52.9%), Oxycontin (0% vs. 11.8%), and Lyrica (9.1% vs. 23.5%) less frequently than
participants who did not initiate NAC.

Table 5.
Pain medications prescribed at study enrollment (N=28)
Medication

Whole sample
(n=28)

Hydrocodone
Tramadol (Ultram)
Oxycodone
Morphine
Oxycontin
Hydromorphone
Fentanyl

Initiated NAC Did not
(n=11)
initiate NAC
(N=17)
9.1%
23.5%
36.4%
52.9%
54.5
35.3%
9.1%
11.8%
0
11.8%
9.1%
0
9.1%
0

Gabapentin
Lyrica
Nortryptyline

81.8%
9.1%
9.1%

41.2%
23.5%
0

57.1%
17.9%
3.6%

Cymbalta

0

5.9%

3.6%

61

17.9%
46.4%
42.9%
10.7%
7.1%
3.6%
3.6%

While pain medications were reported at study enrollment, stable pain medication and PRN
medication were not differentiated until participants returned for Baseline visit 1. Therefore, this
information is only available for the N = 11 individuals who began the open label trial of NAC. The
PRN opioid and stable pain medications prescribed to this subgroup are summarized in Tables 6 and
7, respectively. Detailed descriptions of PRN opioid and stable pain medications, dosage and
frequency for all study participant who initiated study medication are presented in Table 8.

Table 6.
PRN opioid medications of participants initiating NAC (N=11)
Hydrocodone
Hydromorphone
Oxycodone
Tramadol

9.1%
9.1%
45.5%
36.4%

Table 7.
Stable pain medications of participants initiating NAC (N=11)
Gabapentin
Fentanyl Transdermal
Methadone
Morphine
Oxycodone

63.6%
9.1%
9.1%
9.1%
9.1%
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Table 8.
Stable and PRN pain medications of participants initiating NAC (N = 11)
Participant Stable dose medication
002
Morphine 15mg. 1 tab every 12 hours
003

Methadone 10mg. 2 tabs every 8 hours

006

Oxycodone 10mg. 1 tab every 4 hours

007
012

Fentanyl 50 mcg/hr, replace every 72
hours
Gabapentin 600mg. 2 tabs 2x day

013

Gabapentin 300mg. 1 tab 2x day

016

Gabapentin 300mg. 1 tab AM, 2 tabs PM

017

Gabapentin 800mg. 1 tab 3x day

019
022

Gabapentin 300mg. 1 tab in AM, 2 tabs
in PM
Gabapentin 400mg. 1 tab 3x day

024

Gabapentin 300mg. 1 tab 3x a day

PRN medication
Oxycodone 5mg. 1 tab every 8
hours as needed
Hydromorphone 4mg. 1 tab
every 4 hours as needed
Tramadol 50mg. 2 tabs every 8
hours as needed
Oxycodone 10mg. 1 tab 4x day
as needed
Oxycodone 5mg. 1 tab every 8
hours as needed
Tramadol 20mg. 1 tab every 6
hours as needed
Tramadol 50mg. 2 tabs every 8
hours as needed
Oxycodone 5mg. 1 tab 4x day
as needed
Hydrocodone 7.5mg. 1 tab
every 6 hours as needed
Oxycodone 30 mg. 1 tab every
6 hours or as needed
Tramadol 50mg. 1 tab every 6
hours as needed.

Eleven participants started NAC medication. Ten of those participants completed the full
four week course of study medication. One participant experienced an allergic reaction (e.g.
"itching") while taking the NAC medication and attributed the allergic reaction to the NAC. It is
unclear if the reaction was to the NAC medication or to other causes, however the Primary
Investigator, in consultation with the study physician, elected to discontinue the participant in the
study.

63

Primary Analyses
Hypothesis 1. Compared to baseline, study participants will report a reduction in their use of
opioid medications to manage breakthrough pain, using measures of daily morphine equivalent dose
(MED).
The first hypothesis, using a mixed linear model and MED tracked daily, examined whether
there was a decrease in overall opioid use, measured as daily MED, during the three distinct phases
of the study (Pre-NAC, NAC, and Post-NAC). In this model the interaction term was not significant
(F38, 512 = 0.57, p = 0.9822), therefore it was dropped from the model and the model was refit using
the main effects of day/time and NAC use. In the reduced model neither the effect of day/time (F86,
550

= 0.89, p = 0.7367) nor NAC use (F1, 550 = 0.15, p = 0.6973) was a significant predictor of daily

MEDs, partial eta squared =.0003. The results are summarized in Tables 9-11.

Table 9.
Descriptive statistics for MEDs across study phases

Period
Pre
NAC
Post

n

Mean
174
286
187

101.24
104.560
88.03

Standard Deviation
89.93
96.66
102.70
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Standard Error
6.82
5.72
7.51

Daily MEDs by Study Phase
110
105
100
95
Daily MEDs

90
85
80
75
Pre-NAC

NAC

Post-NAC

Figure 7. Mean daily MEDs across 3 study phases

A Mixed Linear Model was fit to the data to examine the impact of time and NAC use on the
Average pain score for each day. In this model the interaction term was not significant (F38, 567 =
1.00, p = 0.4788) therefore it was dropped from the model and the model was refit using only the
main effects of day/time and NAC use. In this reduced model neither the effect of day/time (F86, 605
= 0.84, p = 0.8394) nor NAC use (F1, 605 = 1.73, p = 0.1891) was a significant predictor of average
pain score, partial eta squared =.0029.

Table 10.
Descriptive statistics for Average pain ratings across 3 study phases.

Period
Pre
NAC
Post

n
180
308
214

Mean
6.38
5.95
6.80

Standard Deviation

Standard Error
1.58
1.96
1.18

65

0.12
0.11
0.08

Average Pain by Study Phase
10
9
8
7
6
5

Daily Average Pain

4
3
2
1
0
Pre-NAC

NAC

Post-NAC

Figure 8. Mean Average pain ratings across 3 study phases

A mixed linear model was fit to the data to examine the impact of time and NAC use on the Highest
pain score for each day. In this model the interaction term was not significant (F38, 566 = 0.60, p =
0.9714) therefore it was dropped from the model and the model was refit using only the main effects
of day/time and NAC use. In this reduced model neither the effect of day/time (F86, 604 = 0.80, p =
0.9038) nor NAC use (F1, 604 = 0.30, p = 0.5841) was a significant predictor of highest pain score,
partial eta squared =.0005.

Table 11.
Descriptive statistics for Highest pain ratings across 3 study phases.

Period
Pre
NAC
Post

n
180
308
213

Mean
7.47
6.94
7.91

Standard Deviation

Standard Error
1.85
2.33
1.30

66

0.14
0.13
0.09

Highest Pain by Study Phase
10
9
8
7
6
5
4
3
2
1
0

Daily Highest Pain

Pre-NAC

NAC

Post-NAC

Figure 9. Mean Highest pain ratings across 3 study phases

A mixed linear model was fit to assess the effect of NAC on daily MED throughout the study
(Baseline 1 thorough 4-Week Follow-up). No significant effects were found for NAC on MED.
Additionally, a mixer linear model was fit to Average and Worst pain and no significant effects were
found for either. Given the small sample size, the results cannot be fully interpreted. Effect sizes
were presented for decreases in MED as well as average and worst pain ratings.

Hypothesis 2. Past week VAS severity ratings for Average, Worst and Least amount of pain
will be lower over the 4-week clinical trial period than those reported at baseline.
The second hypothesis was tested with RMANOVA using VAS ratings obtained weekly
about average, worst and least severe pain experienced during the previous week. Assessment time
points included Baseline Weeks 1 and 2, Treatment Weeks 1-4 and 4-Week Follow-up. Analyses
were conducted separately for the 3 pain categories (average, worst, least). The results are
summarized in Tables 12-14.
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A repeated measures analysis of variance was conducted to compare average pain ratings
from the VAS across all study time points. There were no significant effects for time, Wilks'
Lambda = .173, F (6, 4) = 3.189, p = .141, multivariate partial eta squared = .827, ω² = .003.

Table 12.
Descriptive statistics for Average VAS ratings across all study visits.
Study appointment
N
Mean
Baseline 1
10
69.80
Baseline 2
10
71.40
Treatment 1
10
60.30
Treatment 2
10
61.60
Treatment 3
10
62.50
Treatment 4
10
65.90
4-week follow up
10
64.00

Figure 10. Average VAS ratings across all study visits
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Standard Deviation
13.32
15.02
18.09
18.14
19.42
21.13
17.98

A repeated measures analysis of variance was conducted to compare highest pain ratings
from the VAS across all study time points. There were no significant effects for time, Wilks'
Lambda = .453, F (6, 4) = 0804, p = .615, multivariate partial eta squared = .547, ω² = .001.

Table 13.
Descriptive statistics for Highest VAS ratings across all study visits.
Study appointment
Baseline 1
Baseline 2
Treatment 1
Treatment 2
Treatment 3
Treatment 4
4-week follow up

N
10
10
10
10
10
10
10

Mean
86.60
89.30
84.10
83.60
78.80
80.30
82.80
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Standard Deviation
12.24
11.66
16.41
16.87
18.54
19.64
19.65

Figure 11. Highest VAS across all study visits.

A repeated measures analysis of variance was conducted to compare least pain ratings from
the VAS across all study time points. There were no significant effects for time, Wilks' Lambda =
.521, F (6, 4) = .613, p = .718, multivariate partial eta squared = .479, ω² = .003.

Table 14.
Descriptive statistics for Least VAS ratings across all study visits.
Study appointment
Baseline 1
Baseline 2
Treatment 1
Treatment 2
Treatment 3
Treatment 4
4-week follow up

N
10
10
10
10
10
10
10

Mean
43.90
38.80
41.30
46.20
47.10
48.70
45.40
70

Standard Deviation
14.08
17.82
19.59
21.48
22.30
20.28
20.40

Figure 12. Lowest VAS ratings across all study visits

To explore possible changes across the three distinct phases of treatment (Pre-NAC, NAC,
and Post-NAC) a RMANOVA was conducted on the mean pain rating for each phase of the
treatment. Analyses were conducted separately for the 3 pain categories (average, worst, least). The
results are summarized in Tables 15-17.
A RMANOVA was conducted to compare Average pain ratings from the VAS across the
three phases of the study. There were no significant effects for time, Wilks' Lambda = .677, F (2, 8)
= 1.911, p = .210, multivariate partial eta squared = .323, ω² = .027.

Table 15.
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Descriptive statistics for Average VAS ratings across 3 study phases.
Study appointment
Pre-NAC
NAC
Post NAC

N
10
10
10

Mean
70.60
62.57
64.00

Standard Deviation
13.89
17.95
17.98

Figure 13. Average VAS ratings across 3 study phases.

A RMANOVA was conducted to compare worst pain ratings from the VAS across the three phases
of the study. There were no significant effects for time, Wilks' Lambda = .678, F (2, 8) = 1.904, p =
.211, multivariate partial eta squared = .322, ω² = 0.017.
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Table 16.
Descriptive statistics for Highest VAS ratings across 3 study phases.
Study appointment
Pre-NAC
NAC
Post NAC

N
10
10
10

Mean
87.33
81.70
82.80

Standard Deviation
11.81
16.42
19.66

Figure 14. Highest VAS ratings across 3 study phases

A RMANOVA was conducted to compare least pain ratings from the VAS across the three phases of
the study. There were no significant effects for time, Wilks' Lambda = .887, F (2, 8) = .508, p =
.620, multivariate partial eta squared = .113, ω² = -0.003.
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Table 17.
Descriptive statistics for Least VAS ratings across 3 study phases.
Study appointment
Pre-NAC
NAC
Post NAC

N
10
10
10

Mean
41.40
45.83
45.40

Standard Deviation
14.26
20.52
20.40

Figure 15. Least VAS ratings across 3 study phases

Repeated measures analysis of variance were performed to assess the effect of NAC on VAS
ratings (average, worst, least) across all study visits. No significant time effects were found for
NAC on global pain ratings measured through the VAS. Additionally, repeated measures analysis of
variance were performed to assess the effect of NAC on VAS ratings (average, worst, least) across
the three distinct phases of this study (Pre-NAC, NAC, Post-NAC). No significant time effects were
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found for NAC on global pain ratings in the different phases of the study measured through the
VAS. Given the small sample size, the results cannot be fully interpreted. Effect sizes were
observed for improving global pain ratings while taking the study medication.

Hypothesis 3. Upon completion of the 4 week medication trial, participants will have higher
physical and mental health related quality of life scores (as measured by the Short Form-12 survey)
than obtained at baseline.
To test the third hypothesis, that the addition of NAC will result in improvements of health
related quality of life (HRQoL), paired-samples t-test were used to compare Baseline 2, Treatment
period 4, and 4-Week Follow Up assessment data. Changes in HRQoL were measured using two
subscores derived from the SF-12, the Physical Component Summary (PCS) and the Mental
Component Summary (MCS) score. Paired-samples t-tests were run for both the MCS and PCS
scores derived from the SF-12 across the three time points. Results are presented in Figure 16 and
17.

A paired samples t-test was conducted to evaluate the impact of the NAC medication on participants
HRQoL. There were no statistically significant changes in the PCS scores between Baseline 2 (M =
27.53, SD = 8.68) to Treatment period 4 (M =28.63, SD = 10.73), t (9) = -.74, p = .48, Cohen's d = 0.113.

There were no statistically significant changes in the PCS scores between Baseline 2 (M = 27.53, SD
= 8.68) and 4-Week Follow-up (M =27.40, SD = 7.45), t (9) = .09, p = .93, Cohen's d = -.016).
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There were no statistically significant changes in the PCS scores between Treatment period 4 (M
=28.63, SD = 10.73) and 4-Week Follow-up (M =27.40, SD = 7.45), t (9) = .70, p = .50, Cohen's d =
.133.

There were no statistically significant changes in the MCS scores between Baseline 2 (M = 52.86,
SD = 11.24) to Treatment period 4 (M =49.64, SD = 11.24), t (9) = 1.40, p = .20, Cohen's d = .261.

There were no statistically significant changes in the MCS scores between Baseline 2 (M = 52.86,
SD = 11.24) and 4-Week Follow-up (M =47.71, SD = 13.20), t (9) = 1.40, p = .29, Cohen's d = .421.

There were no statistically significant changes in the MCS scores between Treatment period 4 (M
=49.64, SD = 11.24) and 4-Week Follow-up (M =47.71, SD = 13.20), t (9) = .35, p = .73, Cohen's d
= .145.

Paired samples t-tests were performed to assess changes in HRQoL across the three time points.
Two different subscores (PCS and MCS), derived from the SF-12, were used to assess these
changes. No statistically significant changes were seen from Baseline 2 to Treatment period 4,
Baseline 2 to 4-Week Follow Up, or Treatment period 4 to 4-Week Follow Up. Given the small
sample size, Hypothesis 3 cannot be fully interpreted. Small effect sizes were observed for study
medication for improving HRQoL.
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Figure 16. PCS scores across 3 study phases.
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Figure 17. MCS scores across 3 study phases.

Hypothesis 4. After completing the 4 week medication trial, participants with a more positive
appraisal of their pain (Low catastrophizers on the pain catastrophizing scale) will have lower Visual
Analogue Scale pain ratings than participants with more negative appraisals of their pain (High
catastrophizers).

To test the fourth hypothesis, a mixed between-within subjects analysis of variance was
conducted to assess the impact pain appraisal (Low catastrophizers, High catastrophizers) on average
VAS ratings for the past week, across three time periods (Baseline 2, Treatment 4, and 4-Week
Follow Up). There was no significant interaction between participants catastrophizing and time,
78

Wilks Lambda = .72, F (2, 7) = 1.38, p = .31, partial eta squared = .28. There was no main effect for
time, Wilks Lambda = .74, F (2, 7) = 1.26, p = .34, partial eta squared = .26, and neither group
showing significant changes in average pain ratings across the three time points (see Table 18). The
main effect comparing the two approaches to pain was significant, F (1, 8) = 13.80, p = .006, partial
eta squared = .633.

Table 18.
Pain catastrophizing and Average VAS pain ratings across 3 time points.

Time period
Baseline #2
Treatment #4
4 week follow
up

High catastrophizers
N
Mean
5
5
5

81.40
82.2
74.4

Standard
Deviation
10.45
11.03
4.72
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Low catastrophizers
N
Mean
5
5
5

61.4
41.4
53.6

Standard
Deviation
12.18
25.47
20.84

Figure 18. Average VAS ratings across three time points for Low and High catastrophizers.

A mixed between-within subjects analysis of variance was conducted to assess the impact pain
appraisal on Worst VAS ratings for the past week, across three time periods. There was no
significant interaction between participants catastrophizing and time, Wilks Lambda = .86, F (2, 7) =
.59, p = .58, partial eta squared = .14. There was no main effect for time, Wilks Lambda = .67, F (2,
7) = 1.74, p = .24, partial eta squared = .33, and neither group showing significant changes in Worst
pain ratings across the three time points (see Table 19). The main effect comparing the two
approaches to pain was not significant, F (1, 8) = 2.62, p = .14, partial eta squared = .25.
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Table 19.
Pain catastrophizing and Worst VAS pain ratings across three time points

Time period
Baseline 2
Treatment 4
4 week follow
up

High catastrophizers
N
Mean
5
5
5

94.60
90.00
87.00

Standard
Deviation
3.00
5.70
6.04

Low catastrophizers
N
Mean
5
5
5

84.00
62.40
78.60

Standard
Deviation
15.05
36.59
28.09

Figure 19. Worst VAS ratings across three time points for Low and High catastrophizers.

A mixed between-within subjects analysis of variance was conducted to assess the impact pain
appraisal on Least VAS ratings for the past week, across three time periods. There was no
significant interaction between participants catastrophizing and time, Wilks Lambda = .67, F (2, 7) =
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.1.75, p = .24, partial eta squared = .33. There was no main effect for time, Wilks Lambda = .78, F
(2, 7) = 1.01, p = .41, partial eta squared = .23, with neither group showing significant changes in
Least pain ratings across the three time points (see Table 20). The main effect comparing the two
approaches to pain (Low catastrophizers, High catastrophizers) was not significant, F (1, 8) = 2.16, p
= .18, partial eta squared = .21.

Table 20.
Pain catastrophizing and Least VAS pain ratings across three time points

Time period
Baseline 2
Treatment 4
4 week follow
up

High catastrophizers
N
Mean
5
5
5

46.6
58.60
50.20

Standard
Deviation
10.97
16.62
18.90
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Low catastrophizers
N
Mean
5
5
5

31.00
35.4
40.60

Standard
Deviation
21.02
23.34
22.83

Figure 20. Least VAS ratings across three time points for Low and High catastrophizers.

A mixed between-within subjects analysis of variance was conducted to assess the impact of two
approaches to pain appraisal (Low catastrophizers, High catastrophizers) on participants' global pain
ratings (average, worst, least), across three time points (Pre-NAC, NAC, Post-NAC). No significant
interactions were found between approach to pain appraisal and global pain ratings across the three
time points. Given the small sample size, Hypothesis 4 cannot be fully interpreted. Main effect
comparing the two types of pain appraisal was significant for difference in the global pain ratings
between the two appraisal approaches and this was unrelated to the intervention.
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Summary of All Participants
Active medication period. Across all study participants (N =10), self-report VAS scores
show Average pain ratings over the course of the study medication period trended downward in N =
4 participants, with the remaining N = 6 participants’ ratings remaining stable compared to baseline.
When participants’ Worst pain ratings were examined, N = 8 remained largely unchanged (flat line),
with a slight decreases for N = 2 participants. For the Least pain ratings, only N = 1 participant
showed a decline over the 4 weeks, with 5 showing no change and 4 showing an increase over the 4
weeks.
Responses on the Pain Disability Index were mixed. Half (N = 5) of the sample reported
largely stable responses from study enrollment through the medication trial while N = 3 reported
consistent decreases in disability after initiating the study medication. Two participants had variable
responses with decreases for one or two weeks followed by a return to baseline ratings during the
active study medication period.
When looking at participants across their reported catastrophizing thoughts, N = 2
participants show increases in catastrophic thinking at the conclusion of the study medication while
N = 4 showed declines and the remaining N = 4 participants showed little or no changes in their
catastrophic thinking.
On the SF-12 quality of life measure, over half (N=6) of participants reported improvements
in physical functioning during the 4-week study period. For mental health quality of life, half of
participants reported no change during the study period, with N = 4 reporting improvements and N =
1 reporting decrements.
Five participants noted a decrease in depressive symptoms during the medication period,
with N = 3 reporting increases and N = 2 reporting no change. Stress was also assessed and while
taking the study medication, N = 5 of the participants reported decreases in their perceived stress and
only N = 1 reported an increase, the remaining participants did not report any change.
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4-Week Follow-up. At the 4-Week Follow-up visit none of the participants reported
continuing the NAC medication despite its availability as an over the counter medication. At the one
month, post-trial follow-up visit, a variety of patterns were seen. For average VAS pain ratings, N =
1 of the participants showed an increase in average pain; N = 2 showed an increase for Worst pain
and N = 2 reported an increase in Least pain scores. The others either stayed stable (N = 8 for
average; N = 8 for worst and N = 3 for Least) or decreased for each rating scale. Half (N = 5) of the
sample reported only minimal changes from study enrollment through the final study visit 4-weeks
on the pain disability index. Of the remaining N = 5 participants, N = 3 reported increases in
disability at the 4-Week Follow-up and N = 2 reported decreases in disability.
Interestingly, over half (N = 6) of the participants reported that their physical functioning
decreased after discontinuing the medication, whereas N = 3 reported an increase in functioning and
N = 1 reported no change. Four participants reported decreases in their mental health quality of life
after discontinuing medication and N = 2 remained stable, while the remaining individuals reported
improvements.
Several participants (N = 4) who reported an initial decrease in catastrophizing thoughts from
baseline reported increases in catastrophic thinking after the medication trial ended. Alternatively, N
= 2 participants who reported an increase in catastrophic thinking after starting the medication
reported a decrease in catastrophic thoughts after discontinuing the medication.
After the study medication was discontinued, N = 3 participants reported decreases in their
depressive symptoms while the remaining reported no changes. When the study medication was
discontinued, N = 3 participants reported increases in their stress while N = 2 reported decreases,
the remaining N = 5 reported no changes.
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Case Studies
Given the sample size, both clinical and statistical considerations suggest the value of stepping down
from the aggregate and focusing on the individual. Presented below are three case narratives of
participants enrolled in the NAC study. Cases were chosen to illustrate the range of participant
responses to the NAC medication; more effective, less effective, and mixed response.

Participant 017. Participant 017 (DR) was a 52 year old African American female. She was
on disability (physical) and unemployed. She did not smoke and was single. Her medical problems
included: chronic pain, left shoulder pain, carpal tunnel syndrome, diabetes, degenerative disc
disease with sciatica and radiculopathy, coronary artery disease, diastolic dysfunction, chronic
obstructive pulmonary disease, gastroesophageal reflux disease, hiatal hernia, Lymphedema, morbid
obesity, obstructive sleep apnea, hypertension, uterine fibroids, and depression. She was prescribed
and reported taking acetaminophen-oxycodone (Percocett) and Gabapentin for her neuropathic pain.
She reported taking the same dose of acetaminophen-oxycodone (5mg 4x per day as needed) and
Gabapentin (800mg three times a day) for the 9 months prior to study enrollment. In addition, she
was prescribed the following for non-pain related conditions: loratadine, metformin, venlafaxine,
verapamil, medroxyprogesterone, albuterol, Symbicort, esomeprazole, ferrous sulfate, Flonase, lasix,
potassium chloride, and spironolactone. She also reported taking Aspirin (81mg/day). The
participant discontinued her Symbacort between Treatment Visit 2 and 3 and was started on Flovent.
DR enrolled in the study and expressed interest in "anything that might help" her pain. She
scored a 4 on the ID-PAIN scale (-1 to 5), reporting that her pain felt "like pins and needles",
"hot/burning", "electric shocks", and was "made worse with the touch of clothing or bed sheets".
She participated in all her treatment visits and completed Daily Monitoring Forms as instructed
throughout the study. Between the week 3 and 4 Treatment Visits, however, DR experienced
stomach flu, with symptoms she reported made her unable to take her NAC or "much" of her pain
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medication during this time period. The participant reported that she took her NAC (1200mg),
gabapentin (800 mg), and acetaminophen-oxycodone (5 mg) on 3/17/15 at 6pm and next reported
taking her NAC (1200mg), gabapentin (800 mg), and acetaminophen-oxycodone (5 mg) on 3/20/15
at 6pm. She missed 5 scheduled doses of the study medication and these were confirmed during
weekly pill counts.
Her self-report Visual Analogue Scale (VAS) ratings (Figure 21) show that her highest and
lowest pain experienced over the course of the study remained stable or with a slight downward
trend. Her average pain, reported at weekly visits, shows a noticeable decrease following NAC
initiation. Her mean average pain rating prior to taking NAC was 93 (SD = 7) and while taking
NAC was 71.25 (SD = 18.2). A slight return to pre-NAC VAS scores are observable at her
treatment period 4 visit, likely a result of having the flu and not being able to take NAC or pain
medications. By removing this aberrant pain rating and treating Treatment 3 as her last treatment
visit a mean pain rating of 62.67 (SD = 7.37) was observed.
Her responses in the Pain Catastrophizing Scale (PCS) show (Figure 22) that there is an
overall decrease in catastrophizing thoughts and decreases in 'Rumination', 'Magnification', and
'Helplessness' while taking the NAC medication. These measures of catastrophizing returned close
to pre-NAC levels after NAC was discontinued, with the exception of 'Magnification', which
remained stable after stopping NAC. Self-report pain disability ratings (PDI), where zero indicates
no disability and 10 indicates complete disability, a downward trend is visible after she starts the
study medication (Figure 24). She reported no disability in 5 of 6 areas after her final week of
medication. Her PDI scores generally increased across 5 of 6 areas at her 4 week follow up visit.
Her responses to the Perceived Stress Scale (PSS) also showed a decrease from 18 at Baseline to
11.50 (SD=1.29) while taking NAC (assessed at multiple time points) and rebounded to 23 after she
discontinued taking the NAC medication (Figure 25). There was no discernible pattern for the
variations in her rating of depressive symptoms (Figure 23)
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During the treatment phase of the study she subjectively reported, at different treatment
visits, that she "knows it helps nerve damage" and that NAC "helps with stingy and needle feeling"
in her feet. Additionally, the participant reported that the medication is "helping neuropathic pain"
and that she has felt a decrease in neuropathic pain in her hands. Despite the subjective reports of
improvement while taking NAC, the participant did not report taking the medication after it was no
longer provided for her study participation. No reason for not taking the NAC medication was given
by the participant.
No serious adverse events were reported during study participation. She reported several
side effects which included nausea (ongoing), diarrhea (ongoing), hot flashes (reported 1 time only),
and acid reflux (reported 1 time only). Reports of side effects were mild and NAC was generally
well tolerated.
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Figure 21. VAS ratings provided by participant #017.
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Figure 22. Pain catastrophizing scores for participant #017.
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Figure 23. PHQ-9 scores of depression for participant #017.
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Figure 24. Pain disability for participant #017.
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Figure 25. Perceived Stress Scale for Participant #017.

Participant 007. Participant 007 (RJ) was a 43 year old African American female. She was
married and did not smoke. She was not on disability but did have a disability case pending
(physical). She was employed part time. Medical problems included: lupus, chronic abdominal
pain, depression, kidney infection, and gastric bypass. She was prescribed oxycodone (10mg 4x per
day as needed) as a PRN opioid medication and the Fentanyl transdermal patch as a stable pain
medication (50 mcg/hr, replace every 72 hours) for her neuropathic pain. She reported receiving the
same prescription of the oxycodone for at least 2 years before entering the study and the same
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prescription of Fentanyl transdermal patches for 7 months prior to starting the study. Additionally
medications, for non-pain related conditions, included: cyanocobalamin, esomeprazole, lasix,
Golytely Powder, hydroxychloroquine, magnesium citrate, potassium chloride, zinc sulfate, Senna,
amitriptyline, duloxetine. She also used the following over the counter medications: Vitamin A,
Vitamin E, and a daily multivitamin. All medications were confirmed through chart review.
She scored a 3 on the ID-PAIN scale (-1 to 5), and endorsed that her pain felt "like pins and
needles", "hot/burning", and "electric shocks". Her self-report VAS ratings (Figure 26) show that
her Highest, Lowest and Average pain experienced over the course of the study remained stable or
with a slight upward trend. As shown in Figure 27, her responses on the PCS show there was an
overall decrease in catastrophizing thoughts and decreases in 'Magnification' and 'Helplessness'
while taking the NAC medication. These measures of catastrophizing returned to pre-NAC levels
after NAC was discontinued. 'Rumination' remained stable throughout the intervention and after
discontinuation of the NAC. Her responses on the PSS also show a general downward trend while
taking the study medication which continues after the medication was discontinued (Figure 28). She
showed a decrease in pain related disability across all areas of functioning but a return to at or above
baseline levels toward the end of taking the NAC medication was observed (Figure 29). There was a
general downward trend in depression symptoms (PHQ-9) which continued after discontinuation of
the study medication (Figure 30)
The participants subjective responses to the NAC medication were positive. She reported
"possible" improvements in her pain after the first week. After the second and third weeks of taking
the medication she reported that she thinks the "medication is helping ". No side effects were
reported by the participant while taking the NAC medication. The participant did not report taking
the medication after it was no longer provided for her study participation and no reason for not
taking the NAC medication was given by the participant.
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Figure 26. VAS ratings provided by participant #007.

Figure 27. Pain catastrophizing scores for participant #007.
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Figure 28. Perceived Stress Scale for Participant #007.
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Figure 29. Pain disability for participant #007.
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Figure 30. PHQ-9 scores of depression for participant #007.

Participant 024. Participant 024 (GF) was a 43 year old Caucasian male. He was single and
did not smoke. He had a disability case (physical) pending and was unemployed. Medical problems
included: critical monopathy, nerve pain, chronic pain, shoulder pain, diabetes, diabetic neuropathy,
congestive heart failure, coronary artery disease, asthenia, hyperlipidemia, burst blood vessel in eye,
seasonal allergies. He was prescribed Tramadol as a PRN (as-needed) opioid medication and
Gabapentin for his neuropathic pain. He reported being prescribed the same dose of Tramadol (50
mg every 6 hours as needed) and Gabapentin (300 mg three times a day) for 6 months prior to
entering the study. In addition, he was prescribed the following for non-pain related conditions:
atorvastatin, lipitor, warfarin, clopidogrel, furosemide, insulin isophane, insulin lispro, losartan,
metoprolol, nitroglycerine, trazodone, rivaroxaban, lasix, and spironolactone. All medications were
confirmed through chart review. His Gabapentin was increased (600 mg three times per day) 4 days
before the final study visit (4 week follow up) and his Warfarin was discontinued at the same time.
He scored a 4 on the ID-PAIN scale (-1 to 5) and endorsed that his pain felt "like pins and needles",
"numb", "electric shocks", and that is it "made worse with the touch of clothing or bed sheets".
His self-report VAS scores (Figure 31) shows that his Highest and Lowest pain ratings
remained stable or with a slight upward trend. His Average pain rating shows a decrease after he
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starts taking the NAC medication. A slight return to pre-NAC VAS ratings are observable at his 4week post treatment visit. His responses on the PCS show (Figure 32) increases in 'Rumination',
'Magnification' and 'Helplessness' from baseline to the Treatment 4 visit and then the same or
increasing catastrophizing at the 4-week follow up. An overall decrease in perceived stress (Figure
33) is after starting the study medication and an increase after he discontinued taking the NAC
medication, though it did not return to baseline, was observed. A slight improvement in 'life support
activities' and 'sexual behavior' is seen while taking the study medication with a worsening after
discontinuing NAC (Figure 34). An increase in disability is observed for 'recreation' and 'social
activity' after starting the study medication. There was a general decrease in depressive symptoms
while taking the study medication which were maintained at the 4-week follow up visit (Figure 35).
Study measures show a mixed response with decreases in perceived stress and depression symptoms
while showing increases in catastrophizing, pain related disability and no appreciable changes in
pain ratings.
The participant reported his subjective impressions of the effect of the study medication at
several of his follow up appointments. He reported that he did not observe any changes in his pain
or functioning while taking the study medication but did not have any adverse reactions to the NAC.
At his final treatment visit he reported no changes in his pain as a result of the study medication and
that he "isn't sure it is helping". The participant did not report taking the medication after it was no
longer provided for his study participation reports that he "did not take any NAC since last" because
he "didn't feel it was helpful". No Adverse Events were reported by the participant.
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Figure 31. VAS ratings provided by participant #024.
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Figure 32. Pain catastrophizing scores for participant #024.
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Figure 33. Perceived Stress Scale for Participant #024.
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Figure 34. Pain disability for participant #024.
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Figure 35. PHQ-9 scores of depression for participant #024.
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Discussion
The present study was an open label medication trial focused on changes in pain ratings,
medication use, and quality of life associated with an over-the-counter pharmaceutical drug and
nutritional supplement, N-acetyl-L-cysteine (NAC). Study participants were VCUHS patients being
treated with PRN opioid medication and prescribed a stable dose of opioid medication, or gabapentin
for neuropathic pain. The primary outcome variables included Visual Analogue Scale pain ratings
and morphine equivalent doses of opioid medications. The study tested hypotheses that addition of
the study medication would be associated with a decline in pain ratings (VAS scores), reductions in
PRN opioid pain medication use, and improvements in physical and mental health-related quality of
life scores. Further, it was hypothesized that participants with a more positive appraisal of their pain
(Low catastrophizers) would report lower pain ratings while taking study medication than
participants with more negative appraisals of their pain (High catastrophizers).
A total of N = 28 participants were recruited but only N = 11 completed baseline and began
the active medication phase of the study. Of these, N = 10 completed the 4 week medication trial
and follow up visit. While the smaller than anticipated sample size limited testing and interpretation
of formal study hypotheses, the rich dataset for the N = 10 participants who completed the study
afforded an excellent opportunity for qualitative evaluation of study findings. This is timely, given
increased recognition that small-scale pilot studies represent an important, and often essential, step
in the development and evaluation of novel interventions (Moore, Carter, Nietert & Stewart, 2011;
Leon, Davis & Kraemer, 2011). Specifically, the present study provides valuable data on the
feasibility and acceptance of recruitment, retention, and assessment procedures that were integral to
study design. As such, these data will likely contribute not only from a scientific, but also a practical
perspective, to future research with NAC. In addition, lessons learned through the conduct of this
study will be invaluable to the design and conduct of future pharmacological as well as psychosocial
interventions for this important population of chronic neuropathic pain patients.
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NAC and use of PRN opioid medication.
For the sample as a whole, when baseline was compared to the medication trial and 4-week
post-trial follow-up, no change was observed in self-administration of MED across the 3 phases. At
the individual level, however, 4 of 10 participants (30%) showed a 10% or greater decrease in daily
MEDs from baseline to treatment, with the other participant values remaining approximately stable.
None of the participants reported increases of their MED during NAC. Changes in the MEDs for the
whole sample were quite small from Pre-NAC to NAC (3.1% more MEDs while taking NAC).
Similarly, while there was no change overall at 4-Week follow-up, 4 of the participants
showed a 10% or greater increase in their daily MEDs from treatment to 4-week follow-up while one
participant showed a decrease of at least 10%. This observation is complicated by the fact that total
MEDs for the whole sample from decreased by 15.81% from NAC to Post-NAC. Given that no
participants reported continuing NAC after the study medication was no longer provided, this drop is
not attributable to the study medication. Likely, the resulting drop in MEDs is attributable to
prescription changes for PRN opioid and stable pain medication reported by 4 of the participants.
Several factors may have contributed to the lack of change in MEDs during the NAC trial
period. First, NAC may not be a promising adjuvant in the treatment of chronic neuropathic pain.
Second, NAC may have had an effect, but only in a subgroup of study participants, and small sample
size clouded this effect. This possibility warrants further study, to determine if participants with
some reduction in MED administered during the trial differ in some way from those who did not.
For example, were participants prescribed Gabapentin as their stable dose medication for
neuropathic pain more or less likely to show a change than those with a stable dose opioid
medication?
Another contributing factor may be the way in which chronic pain patients used their PRN
medications. This approach to pain management is designed to provide flexible and safe dosing and
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meet the individual’s unique needs. However, it was apparent during the conduct of the study that a
number of study participants, rather than taking PRN medications in response to breakthrough pain,
were instead taking them primarily in a time-dependent manner similar to that of their stable dose
medication schedule. Pasero and colleagues (1999) report that pain is often undertreated because
physicians under prescribe opioid analgesics (order inappropriately low doses or prolonged dosing
intervals). This under prescribing could prompt the patient to utilize their PRN medications in the
stable manner we observed to bridge the gap in their pain management regimen.
Another possibility for understanding this stable use of opioid is through the findings of
Kwon and colleagues (2015), that PRN opioid medications were sometimes used not only in
response to acute elevations in pain, but also as a means of chemically coping with stress. A
potential stress among the current population is likely to be the fear of breakthrough pain and as
such, the opioid medication may be used prophylactically to avoid the experience of breakthrough
pain. This pattern, motivated by avoidance of pain, would make a reduction in MED taken during
NAC unlikely, as the PRN medication was taken in advance of experiencing the pain.
The use of PRN medications to avoid break through pain could also impact pain severity
ratings, limiting the range of pain severity experienced by some participants. That is, if PRN
medications are taken in anticipation of impending pain, to avoid experiencing the pain, then the
range of pain experienced may be more circumscribed. A possible interpretation of the lack of
significant or consistent changes in MED in the current study is found when we consider these
results in the context of a fear-avoidance (FA) model of chronic pain. According to this model, a
cycle is initiated when pain is catastrophically interpreted and this interpretation gives rise to painrelated fear, avoidance/escape behaviors and hyper vigilance. In chronic pain, this maladaptive
process serves to further entrench fear and avoidance of new behaviors (or a return to previous
behaviors) and hypervigilance to pain experiences even when pain may be lessened (Turk & Wilson,
2011).
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In the context of the current study, the lack of consistency to the reported changes in MED
might be related in part, to a fear avoidance approach that chronic pain participants sometimes have
toward their pain. Research supports the validity of the FA model for chronic pain (Crombez,
Eccleston, Van Damme, Valaeyen, & Karoly , 2012), and suggests the effectiveness of exposurebased pain treatment. For instance, results from a recent study in a primary care setting found that a
brief (one session) exposure-based intervention produced measureable changes in fear avoidance
beliefs and functioning for patients with chronic pain (Guck, Burke, Rainville, Hill-Taylor, &
Wallace). A behavioral intervention, such as the one utilized by Guck and colleagues (2015), could
help to challenge the entrenched fear and avoidance found among chronic pain patients that might be
preventing them from recognizing changes in their pain as a result of a novel medication.
Alternatively, it is also possible that some participants did not change their opioid medication
use because of a well-learned pattern of behavior. Chronic pain patients, at the individual level have
learned how their pain manifests itself and what the progression or escalation of pain symptoms will
be like. In an attempt to manage this cycle, some may take pain medications regularly in concert
with pain fluctuations they have learned over time. With such individuals, we might see a decrease
in pain severity ratings but we are less likely to see a change in MEDs. That is, they could continue
to take their usual doses of medication while also reporting a reduction in pain symptom severity.
This warrants further study, looking first at MED data in concert with the Average and Highest pain
ratings reported by patients for the same period of time.

NAC and pain severity ratings.
Average pain ratings while taking NAC, for nearly 2/3rds (60%) of the sample, did not
change significantly from those collected at Baseline, with 80% of participants showing this same
pattern for worst (most severe) pain ratings. This was not seen for lowest level of pain, with nearly
half of participants reporting an increase during NAC administration, with further increase at 1
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month follow-up. McCraken (1997) found that people who report greater attention to pain also
report higher pain intensity. It is possible that the frequent tracking of their pain ratings throughout
the week resulted in an increased attention to lower intensity pain and a resulting increase in the
perception of pain.
A point to consider is the differences in retrospective recall of pain ratings versus daily
tracking of pain ratings. The current study measures focused on 1-week recall of pain. One study
showed a high correlation between 1-week recall of average pain intensity and estimates of average
pain intensity from a daily diary (Jensen et al., 1996). Another study showed that alternative
measures of retrospective recall (e.g. least pain, average pain, worst pain) were highly correlated
with daily recordings, however average pain ratings tended to be most highly correlated (r=0.78)
(Jensen et al., 1998). While retrospective pain recall is relatively stable it could be beneficial in
future studies to compare both the daily pain ratings with the retrospective recall pain ratings to
assess stability.

NAC and Quality of Life.
When quality of life measures were examined, physical ratings were unchanged and
remained relatively stable throughout the study. Mental health ratings, however, showed a
downward trend suggesting improvements in mental health functioning while on the study
medication and continuing through 4-Week Follow-up.
There was not a large enough sample size to power the proposed analyses, however effect
sizes could be measured. Effect size measures the magnitude of a treatment effect, and unlike
significance tests these indices are independent of sample size (Dattalo, 2007). As such, the effect
sizes are interpretable. While the majority of the effect sizes suggest that there was a small or, in
some cases, negligible treatment effect there are a few instances worth noting. Effect sizes observed
suggest that the medication may have beneficially impacted the participants’ responses on the
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Mental Component Summary (MCS). This effect size was small from Baseline 2 to Treatment 4
(Cohen's d = .261) and from Treatment 4 to 4-Week Follow-up (Cohen's d = .145), however it was
approaching a medium effect size (Rice & Harris, 2005) from Baseline 2 to 4-Week Follow-up
(Cohen's d = .421). Additionally, small effects were observed for Average and Worst pain. The
effect sizes observed suggest a real, but difficult to detect effect of NAC on improved mental health
functioning. This finding is bolstered by individual level findings that showed half of the
participants reporting mild improvements in mood while on NAC and decrements in mood when no
longer taking NAC.
The study participants had a large number of other medical problems in addition to their
chronic neuropathic pain (discussed more fully below). Given the scope of medical problems
participants were experiencing and the minimum duration of their pain it seems that the goal of
seeing changes in health related quality of life was overly ambitious. Any changes in health related
quality of life were likely dwarfed by the overwhelming duration and complexity of their
presentation (Kazis, Miller, Clark, Skinner, Lee et al., 1998). It is unreasonable to hope that simply
through the addition of the study medication that the entrenched and chronic response to their pain
would be impacted.
The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) suggest that the impact of a study medication on aspects of well-being and functioning
also be assessed (Turk et al., 2003). Following this recommendation, the current study assessed
HRQoL, to evaluate changes in functioning that may, or may not, accompany changes in pain
experience. As a result of the inclusion of these measures, improvements in mental health
functioning as a result of the study medication were seen. This lends support to the importance of
recognizing the multifaceted nature of chronic pain.
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Catastrophizing and response to NAC.
When data were compared for the Low Catastrophizer and High Catastrophizer groups,
findings were mixed. During the active medication phase, improvements as well as declines were
observed for both Low and High catastrophizers in mental health and physical functioning.
Similarly, mixed findings were also observed when looking at the these two groups at the 4-Week
Follow-up.
With N = 5 per group there was not a large enough sample size to interpret the proposed
analyses, and as such, the findings are limited to observations of the data and individual participant
ratings. An initial review of the data shows that average pain ratings were lower for the Low
catastrophizers than for High catastrophizers. This finding was expected but worth noting because
higher pain catastrophizing scores have been found to be predictive of higher pre-treatment and posttreatment pain ratings, even when controlling for baseline pain (Edwards, Bingham, Bathon &
Haythornthwaite, 2006). Additionally, high levels of catastrophizing predict poorer response to
pharmacological interventions for neuropathic pain (Sullivan et al., 2001). This finding provides
important context for interpreting the observations about the two groups.
A 20 point reduction was observed in Average VAS pain ratings at the Treatment 4 visit and,
to a lesser degree, at 4-Week Follow-up, for Low catastrophizers. Interestingly, a similar drop was
observed for Worst pain ratings but not for least pain ratings (potentially due to floor effects of the
VAS). Upon closer examination of the data, the drop appears to be mostly attributable to one
participant who showed significant decreases in both Average and Worst pain after initiating the
NAC medication. The decreases from Baseline for Average and Worst pain ratings were maintained
at the 4-Week Follow-up. This finding suggests that NAC may have had an impact on reported
average and worst pain ratings in 1 of 5, or 20% of, Low catastrophizers. While it is possible that
this decrease in pain ratings is attributable to other factors, it is worth paying special attention to
Low catastrophizers responses to the NAC medication in future trials.
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No clear patterns were evident in support of the beneficial effects of NAC, however there
were some interesting observations that could warrant further study. In future studies of NAC and
chronic pain it will be important to consider the role that catastorphizing approach has on pain
ratings and response to the medication as well as ways to counteract months or years of disability
related to their chronic pain. Identifying potential groupings of patients who will be more, or less,
responsive for NAC could be essential in assessing the impact of the medication.

Lessons Learned: Informing Future Research
While the smaller than anticipated sample size limited testing and interpretation of formal
study hypotheses, the development, launch and conduct of the study yielded additional information.
Data are available not only for the 10 primary study participants, but also the larger group of patients
that contributed to other study components which culminated in the open-label NAC trial. The
present study is timely, as there is increased recognition of the important role pilot studies play in the
development and testing of novel interventions (Moore, Carter, Nietert & Stewart, 2011; Leon,
Davis & Kraemer, 2011).
The following section presents methodological issues germane to the design and conduct of
the open label NAC trial, highlighting lessons learned and how the data can inform future studies;
not only those focused on NAC, but also more broadly, the research that seeks to expand and
improve treatment options for chronic pain. The discussion is organized temporally, beginning with
early study design and participant identification issues and ending with study follow-up concerns.
The discussion is intended to inform the field from not only a scientific, but also a practical
perspective.
Case identification. The present study planned to use the VCUHS primary care clinic as the
primary site for identification and recruitment of study participants. While it was initially estimated
that approximately 1,500 primary care clinic patients would present with a diagnosis of neuropathic
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pain and that 600 (40%) of these patients would be receiving opioid pain medication, case
identification proved challenging. As previously described, the patient chart review for the 6 month
period (April to November, 2014) was conducted prior to, and through the start of, study enrollment.
Three findings of particular importance, emerged from this review: 1) only 10% of patients had a
diagnosis of neuropathic pain, 2) 13.9% of patients, regardless of diagnosis, were prescribed a stable
opioid, and 3) less than one-third (29.8%) of all patients were prescribed PRN opioid medication.
The chart review affirmed that despite projections for a large pool of potential neuropathic pain
patients who were prescribed opioid medications, far fewer patients were eligible for the study
which significantly hampered recruitment. In the 15 months of active study recruitment, only N =
187 unique and potentially eligible patients were identified through a variety of sources (e.g., chart
review, provider referral).
Neuropathic pain. A diagnosis of neuropathic pain was found in only 10% of patient
records. While this rate was commensurate with national prevalence rates in the range of 1-8% in
the general adult population (e.g., Dworkin et al., 2007; Torrance, Smith, Bennett & Lee, 2006;
Bouhassira, Lantéri-Minet, Attal, Laurent & Touboul, 2008), they were markedly lower than
expected in the target medical clinic. Factors contributing to these lower rates include: under
diagnosing of neuropathic pain and/or cases where neuropathy is viewed as a secondary diagnostic
concern, and therefore not listed, with primary attention given to the disease or condition which lead
to neuropathic pain.
Other studies have found under diagnosis of neuropathic pain to be of concern. Ziegler and
colleagues (2015), for example, in their national educational initiative focused on prevalence of
diagnosed and previously undiagnosed polyneuropathy in primary care settings, found that in their
sample of N = 1017 patients, more than half of those who screened positive for polyneuropathy
through medical history, physical examination and/or clinical testing were previously undiagnosed.
Similarly, Bongaerts and colleagues (2013) found that 91% of patients diagnosed with distal
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sensorimotor polyneuropathy were previously unaware of their diagnosis. These studies affirm that
underdiagnosis can be a serious concern in studies of chronic neuropathic pain.
Another form of underdiagnosis is suggested by Pollack and colleagues (2013), who found
many neuropathic pain diagnoses might be subsumed under the diagnostic label of the associated
condition. This could occur because neuropathic pain is not a single diagnosis but rather a type of
pain that arises as a "direct consequence of a lesion or disease affecting the somatosensory system"
(Treede et al., 2008). For instance, diabetic neuropathy is the result of nerve damage secondary to
vascular problems that occur with diabetes (Pinzur, 2011). While the majority of non-cancer cases
of neuropathic pain can be traced to either diabetes (approximately one-third) or some type of
autoimmune disorder (another one-third), the remaining third are classified as idiopathic, with
unknown pathogenesis or spontaneous origin (Loeser, 2001).
The lower than anticipated rates of chronic neuropathy and the potential for underdiagnosis
suggest that broader, more liberal criteria should be the standard practice for identify cases when
utilizing chart review. In fact, it may be beneficial to focus on other, more consistently identifiable
criteria such as any diagnosis of "any pain" and/or "opioid pain medications" as a preliminary
screening for chart reviews. Such a broad screening approach could then be followed by an
assessment tool such as the ID-Pain questionnaire, a standardized measure that provides specific cutoff scores to identify individuals with neuropathic pain. Future studies should continue this practice.

Stable opioid. Fewer patients were prescribed a stable opioid (13.9%), regardless of
diagnosis, than expected. A stable opioid medication, defined as the same dose and dosing schedule
for at least 6 months, was one of the initial inclusion criteria. Throughout the course of the study
several challenges were identified with the requirement of a stable does of opioid medication for at
least six months before study enrollment; 1) tolerance to opioid medications, 2) reclassification of
tramadol and hydrocodone-based medications, and 3) new prescribing requirements.
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The first challenge for requiring a stable opioid medication in the prior 6 months was related
to tolerance. The inherent nature of opioid medications is that the analgesic efficacy may not be
maintained over time and a level of tolerance can be achieved for patients (Mercadante & Bruera,
2006; Ballantyne & Shin, 2008). With a diagnosis of chronic neuropathic pain, the opioid
medication is acting to mask the pain symptoms, however by its very nature; the cause of the chronic
pain will remain. Given time, the chronic pain patient will receive less analgesic relief from pain as
their body becomes tolerant to the opioid medication. This tolerance to the opioid medication results
in a reemergence of pain symptoms. One approach taken by physicians in response to increased
pain is to increase the dose of the patient’s opioid medication dosage or change the medication to
achieve analgesic efficacy (Ballantyne & Shin, 2008). Either option would result in participant
exclusion.
The second and third challenges were the result of an unforeseen change in the classification
of both stable and PRN opioid medications by the U.S. Drug Enforcement Agency (DEA)
(Pergolizzi, 2015). Effective August 18, 2014, the DEA reclassified Tramadol, a previously
unscheduled synthetic opioid analgesic, as a Schedule IV drug. Minor restrictions were placed on
frequency of prescriptions and limits were placed on number of available refills. More significantly,
effective October 6, 2014, The DEA also rescheduled hydrocodone combination products (i.e.
hydrocodone-acetaminophen) from a Schedule III to the more restrictive Schedule II. The
restrictions resulting from this change were significant; written prescriptions must be provided (no
fax or phone prescriptions), and a new written prescriptions must be provided for any refills. The
change only allows physicians to prescribe these medications for intervals of 30 days or less.
Patients requiring refills were required to visit their physician for a new prescription. Anecdotally,
several patients approached for study enrollment reported recent changes to their pain medication
when they had previously been on a stable dose, thus making them ineligible for the current study.

109

These changes were part of an effort to curb prescription drug abuse and highlight the
recognition that some providers were not closely monitoring their patients opioid medications. The
risks of iatrogenic addiction are a significant safety concern that was, in part, addressed by the DEA
changes. The reclassification of these medications also likely drew attention to prescribing practices
and could have resulted in a more conservative approach toward opioid pain management. While
every effort was made to keep study inclusion and exclusion criteria consistent throughout the
clinical trial, the consistently lower rate at which patients were prescribed stable dose opioids for the
management of chronic neuropathic pain, likely in part due to the above, the decision was made 5
months after study launch to broaden study criteria to include gabapentin.
PRN opioid medication. Finally, fewer patients were prescribed PRN opioid (29.8%),
regardless of diagnosis, than expected. While the percentage approached what we expected to see
they were still low. In addition to sharing many of the same challenges as identified for stable
opioid medications, PRN opioid medication also has the potential to be used as a stable opioid as
discussed previously.

Screening for eligibility. To determine study eligibility, potential participants were
screened to review inclusion/exclusion criteria. For the present study, over 60% of potential
participants were determined ineligible because they did not meet study inclusion/exclusion criteria.
Three criteria are worth discussing more fully: stable dosing, average pain ratings, and exclusion for
medical conditions.
Stable dosing. Another factor that contributed to patient ineligibility came from changes in
medication type or dose. A stable pain medication (opioid or gabapentin) was required for
participation and recent changes in the dose or a switch in medication would make the patient
ineligible for participation. According to Dowell and colleagues (2016), the benefits and harms of
continued opioid therapy should be evaluated every 3 months. A common result of this re110

evaluation can be a switch in medication or change in medication dosages (increase or decrease as is
clinically warranted). This practice along with new scheduling guidelines for some common opioid
medications accounted for a large portion of participant exclusion. While some participant exclusion
was expected because of changes in stable medications the frequency of this occurrence was
surprising.
Pain Rating. Participants were eligible if they reported an average pain rating of > 5 for the
prior week. A cut-off score for pain ratings is necessary for the measurement of the efficacy of a
medication for pain and if no cut-off score had been used a floor effect might have been present
(Vermeersch, Lambert, & Burlingame, 2000). Specifically, the intent of this required pain rating
was twofold; first was to capture patients with significant unmanaged neuropathic pain, and second
to have a moderate pre-treatment pain level which would allow for observable changes in pain
ratings while taking the study medication. Still, it is possible that a balance could be struck between
a lower cut-off score which would allow for the identification of additional eligible participants
while also allowing for the ability to monitor and measure potential changes in pain as a result of
study participation. For instance, one study of neuropathic pain required a > 4 VAS pain rating for
study inclusion (Backonja, Beydoun, Edwards, Schwartz, Fonseca, Hes et al., 1998), while another
required > 3 VAS pain rating (Van de Vusse, Stomp-van den Berg, Kessels & Weber, 2004). While
setting a lower average pain rating for inclusion would not have dramatically changed the
recruitment levels it has the potential for expanding the number of potentially eligible patients.
Additionally, the challenge of the chosen pain rating cut-off is that it requires a participant to
report an Average pain state from moderate to severe. This presents a difficult position for patients
and doctors. A participant with higher pain ratings for the past week might be seeking a change in
their pain medication, excluding them from the study. Alternatively, a patient with a pain rating
below 5 may have recently received a change in their pain medications (e.g. dose escalation, new
medication) to better control their pain, excluding them from the study.
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Exclusions for medical conditions. Another exclusion criterion found for 16% of patients
who were unable to enroll in the study was diagnosis of asthma. Asthma was an exclusion criteria
for study participation because NAC may worsen asthma symptoms and should be used with
caution. For safety reasons, clearly asthma must remain as an exclusion criterion. However, safety
related exclusion criteria can also pose challenges to recruitment that need to be taken into account
for future recruitment. The characteristics of recruitment sites should be thoroughly understood
prior to study launch to help mitigate the impact that these factors may play on recruitment.
Among minority, urban, and low-socioeconomic patients, asthma rates are 11.2% (Akinbami
et al., 2012). In the Ambulatory Care Clinic, where the patient population was majority African
American, urban, and low-socioeconomic status we should expect to see comparable rates. We saw
slightly higher rates for exclusion because of asthma than might have been expected, and double the
rates seen in a general population sample (7.7%) (Cloutier, Wakefield, & Bailit, 2005). This
awareness of the general base rates of necessary exclusion criteria will help to identify an
appropriately sized recruitment pool from which the recruitment goals can realistically be realized.
Asthma was an important exclusion criteria for maintaining the safety of the participants as it
is contraindicated for patients with asthma to take NAC. However, this exclusion criteria will also
pose a limit to the generalizability of findings should NAC prove to be an effective adjuvant for
inadequately managed chronic pain in future studies. The challenges of asthma as an exclusion
criteria were not fully understood when recruitment began and will be important considerations
when planning further study of NAC in this population.
Medical Complexity. The number of medical diagnoses among participants screened for this
study affirmed the complexity of health problems often found co-occurring in inadequately managed
chronic neuropathic pain patients. Of the participants (N = 28) who enrolled in the study, the range
of medical diagnoses identified was 4 to 19 with a mean of 9.3 (SD=4.24). A review of these
diagnoses supports the fact that participants who enrolled in the study presented with serious medical
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conditions (i.e. hepatitis B, hepatitis C, lupus, irritable bowel syndrome, cervical disk disease,
diabetes, atrial fibrillation, chronic pancreatitis), in addition to their chronic pain neuropathic pain.
The exclusion criteria were limited to those conditions that would compromise patient safety (e.g.
asthma) with the goal of offering the study to as many patients as possible.
However, such broad inclusion criteria for the current study allows for the possibility of a
greater variety and complexity of co-morbid medical conditions. The sample was representative of a
"real world" population which allows for greater generalizability, however this poses the obvious
challenge of a complex presentation of medical and psychological diagnoses impacting and
obscuring potential findings.

Provided informed consent. Another time point for participant attrition was after
participants provided informed consent, completing study enrollment, but prior to medication
initiation. Almost two-thirds (60%) of enrolled participants were withdrawn prior to initiating study
medication. This attrition prior to medication initiation was higher than observed in several
medication trials for neuropathic pain, which generally ranged from 16-36% (Rowbotham et al.,
1998; Eisenberg, McNicol & Carr, 2005; Simpson et al., 2010; Campbell et al., 2012; Van Seventer
et al., 2010). None of the studies reviewed reported rates as high as 60%. There were three distinct
groupings for withdrawal observed in the current study: participant initiated, physician prompted,
and change in eligibility. Participants initiated their withdrawal through both active (e.g. requesting
to be withdrawn) and passive (e.g. not responding to study phone calls or attending study
appointments) means. Physician prompted withdrawal was as a result of identification of a
contraindication for study participation, either by the study doctor or at the recommendation of the
participants physician. Finally, participants were withdrawn from the study if their eligibility status
changed prior to medication initiation (i.e. illicit substance use, >5 pain rating).
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There are several possible reasons for the high rate of drop out. One possible reason could be
related, in part, to the limited availability of study staff. While every attempt was made to
accommodate participants scheduling needs the study coordinator and RAs were only able to be in
the clinic part time. It is also possible that the study compensation for enrollment of $5 was enticing
for the indigent care population and that a portion of participants had no intention to continue in the
study after enrollment. Another possibility is the frequency of study visits was overly burdensome
on the participants.
There was one finding of particular interest related to the ID-PAIN measure, completed at
study enrollment. Specifically, 23.5% of participants who did not initiate the medication endorsed 5
symptoms associated with neuropathic pain while only 9.7% of participants who initiated the
medication endorsed the same number. Participants who did not initiate NAC are reporting more
neuropathic pain symptoms than the participants who did initiate the medication. This raises the
question as to whether greater responses on the ID-PAIN are predictive of study withdrawal.
Further, the participants endorsing more items on the ID-Pain may experience greater difficulty in
following through with study procedures (e.g. weekly visits, daily medication and pain tracking),
thus necessitating their withdrawal. This could impact future neuropathic pain studies and should be
monitored closely.
Length of medication trial. Identifying an appropriate length for the medication trial and
dosage of the medication to allow for changes in the underlying symptomotology is also a challenge.
The current study utilized a 4-week period of active study medication, however there is wide
variability within the literature on the duration of active medication within trials, even for the same
medications. The length of duration for taking an active medication in studies varies based on a
number of factors. Medication will reach therapeutic levels depending on the dose, length of time,
and frequency of use. The length of medication trials cannot be compared across different
medications because of their different make up and mechanism of action. However, trials of the
114

same medications (i.e. gabapentin) often have variations in the length of the trial and dosage
administered. This is a common step in assessing the appropriate dosage and length of time until
optimum therapeutic effect is reached. This process can be observed for several prominent
medications currently utilized for neuropathic pain. For instance, in a randomized controlled trials
of gabapentin for the treatment of neuropathy, several different durations and titration approaches
are reported in the literature, including: 4-week dose titration immediately followed by a 4 week
stable dose period (Backonja, Beydoun, Edwards, Schwartz, Fonseca et al., 1998; Serpell, 2002), 1
week titration followed by a 12 week stable dose period(Zhang, Rainka, Freeman, Harden, Bell et
al., 2013) and 2 day titration followed by 6 week stable dose period (Morello, Leckband, Stoner,
Moorhouse, & Sahagian, 1999). Variations were also observed in studies examining pregablin,
including: 1 titration week followed by 11 weeks of stable dose period (Freynhagen, Strojek,
Griesing, Whalen & Balkenohl, 2005), 1 week titration and 6 weeks of stable dose period (Richter,
Portenoy, Sharma, Lamoreaux, Bockbrader, & Knapp, 2005). The dosage and length of medication
trial should not be compared for NAC, however these studies show that variations in length of a
medication trial are a common practice.
Variations in dosage and duration were also observed across the available NAC trials
(Deepmala, 2015). One study, looking at depressive symptoms in bipolar disorder, provided 2000
mg NAC over a 24 week period as an adjunctive to usual medication (Berk et al., 2008). Another
study looking at Tricholtillomania provided 1200 mg daily of NAC for 6 weeks and then increased
the dose to 2400 mg daily for the remaining 6 weeks (Grant, Odlaug, & Kim, 2009). Still others
provided 2400 mg of NAC as study medication daily for 16 days (Amen, Piacentine, Ahmad, Li,
Mantsch et al., 2011), 2400 mg daily for 4 weeks (Roten, Baker & Gray, 2013), 1,200 or 2400 mg
daily for 8 weeks (LaRowe, Kalivas, Nicholas, Randall, Mardikian, Malcolm, 2013), 600 to 900 mg
daily for 10 weeks (Nikoo, Radnia, Farokhnia, Mohammadi, Akhondzadeh, 2015 ), 2400 or 4800 mg
daily for 12 weeks (Garcia, Francis, Dawood, Lai, Faraone, & Perl, 2013; McClure, Baker & Gray,
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2014), 450 to 1200 mg daily for 12 weeks (Miller & Angulo, 2014) and 1000 to 2000 mg daily for
24 weeks (Bernardo, Dodd, Gama, Copolov, Dean et al., 2009).
Among NAC studies, initial therapeutic effect has been observed at variable time points. A
review of NAC for OCD and OCD-related disorders found that doses of 2400 to 3000 mg over an 8
week period were adequate for exerting an initial therapeutic effect (Oliver et al., 2015). A
randomized, double blind, placebo controlled trial prescribed 2400 mg of NAC daily and found a
significant effect from week 9 to the end of the 12 week trial (Grant, Odlaug, & Kim, 2009).
Another study used a 16 week medication period, however the results suggest that a non-significant
trend was observable over the first 12 weeks of the study in support of NAC (Sarris, Oliver,
Camfield, Dean, Dowling et al., 2015). In a study looking at the effect of NAC on cocaine
dependence which looked at both 1200 and 2400 mg dosing over an 8 week period did not find
reductions in cocaine dependence (LaRowe, et al, 2013). Results for the efficacy of NAC after 4
weeks of medication are promising across two addiction studies. One study of NAC on
methamphetamine addiction provided 4 weeks of NAC medication at 1,200 mg and observed
significant reductions in methamphetamine cravings (Mousavi et al., 2015), while another study of
cannabis dependence found that 4 weeks of 2,400 mg of NAC resulted in decreases in self reported
use and cravings but no observable changes cannabis use (Gray et al., 2010).
The variations in both dose and duration are important to consider when investigating the
efficacy of the medication with a new population. After further review of the dose, duration and
when efficacy was observed in other studies, changes in the duration of the medication trial should
be considered. Additionally, the long standing nature of participant pain and medical complexity
may support a longer trial for the identification of potential efficacy of NAC for neuropathic pain
patients.
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Medication initiated. While rates of attrition were high prior to beginning the 4-week trial
of NAC, rates of attrition thereafter were low. Only one participant was withdrawn from the study
due to an adverse reaction (discussed in greater detail below). All of the remaining 10 participants
completed the study. A review of several medication trials for neuropathic pain revealed that
attrition rates after medication initiation, excluding withdrawals due to adverse events, ranged from
4% to 22% (Rowbotham et al., 1998; Eisenberg, McNicol & Carr, 2005; Simpson et al., 2010;
Campbell et al., 2012; Van Seventer et al., 2010). Additionally, adherence was high; all 10
participants completed 100% of their study visits. The rates of completion and adherence were
particularly high after medication initiation in the current study and this is very encouraging for
future medication trials.
Adverse Events. In the current study we saw one participant (9%) withdraw because of an
adverse event. Adverse events to medications are specific to the medication (e.g. dosage, duration,
frequency) and cannot be compared across medication classes. A review of NAC studies that used
2400mg of NAC, and reported withdrawal because of adverse events, showed 0% and 7%
experienced adverse events resulting in study withdrawal (Gray, Watson, Carpenter & LaRowe,
2010; Bloch, Panza, Grant, Pittenger & Leckman, 2013).
NAC was well tolerated with less than half (45%) of participants reporting any adverse
reaction to the study medication. One participant was withdrawn after reporting a potential allergic
reaction, itching, after taking a single dose of the medication. While it is possible that the itching
was a result of the NAC medication, as it is an identified side effect, it is also possible that it was
unrelated to the study medication. Of the remaining participants, only 4 reported any side effects
while taking NAC, and those reported were consistent with the NAC literature which reported
between 43% and 63% of patients having side effects that were either probably or possibly related to
the study medication (McClure et al., 2015; Gray, Watson, Carpenter & LaRowe, 2010; Bloch,
Panza, Grant, Pittenger & Leckman, 2013 ). The most common side effects in the present study
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were nausea (N =3), diarrhea (N = 2), and reflux/heartburn (N = 2). These same side effects were
commonly reported in other studies of NAC as well (Sarris et al., 2015; LaRowe et al., 2006;
McClure et al., 2015; Gray, Watson, Carpenter & LaRowe, 2010; Bloch, Panza, Grant, Pittenger &
Leckman, 2013). Participants generally reported these symptoms as mild and that the nausea and
reflux improved when taking the medication with food. Overall, the limited and mild nature of side
effects is in line with existing literature and suggests that the study medication was well tolerated at
the current dose.

4-Week Follow-up. The original study design did not include a follow up period and in fact
was very informative. Upon suggestion of the dissertation committee a 4-week follow-up was added
to the current study and allowed for the assessment of pain ratings, PRN opioid pain medication use,
and physical and mental health related quality of life scores after the active medication had been
discontinued.
There were two particularly interesting findings from the 4-week follow-up. First, all
participants who completed the medication trial also completed this follow up visit. The follow
through by the study participants was particularly surprising. As was discussed previously, the rates
of follow through in the current study were well above the rates commonly observed in chronic pain
research. This suggests a level of investment in their care, and through that, in the study.
Secondly, at 4-Week Follow-up, all participants reported discontinuing NAC at the end of
the study and none of the participants reported seeking out the NAC medication after it was no
longer provided for their use. Several of the participants provided subjective reports that the NAC
medication was helpful, yet despite this, none of the participants sought to continue the medication.
Possible reasons for this lack continuation of NAC include; cost, difficulty in obtaining NAC, or
belief that NAC did not impact their pain despite subjective reports of changes in pain experience.
NAC is a relatively easy to procure over the counter supplement available in most pharmacies (i.e.
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CVS, Walgreens, Kroger) suggesting that availability was likely not a problem. The cost of NAC
can be variable depending on quantity and brand. A brief search of a national pharmacy chain found
that the least expensive NAC available would cost approximately $30 for a one month supply at the
dosage used in the study (1200 mg twice a day). Given the indigent nature of much of the
recruitment pool, it is very plausible that this was a factor choosing not to continue taking NAC.
Finally, it is possible that participants did not continue the medication because they did not feel it
was helpful for their neuropathic pain. Further qualitative investigation in future studies would be
beneficial in understanding reasons participants did not continue with the supplement.

Study Limitations
The present study had a number of limitations. First, small sample size. We experienced
particularly high rates of attrition prior to medication initiation. These rates of attrition are possibly
related to the time commitment for participation. For example, participants were required to be
present 8 times in a 10 week period. Perhaps the compensation was not adequate for further
participation. participants were responsible for transportation to and from their study appointments
as well associated costs (i.e. parking, bus pass, gas money). Within the indigent care population that
participants were primarily recruited, this might have been overly burdensome. Every attempt was
made to be flexible in scheduling appointments and pairing study visits with other appointments,
however this may not have been sufficient. Additionally, there was a time and effort commitment
necessary for coming to appointments as well as tracking medications and pain ratings throughout
the day for the length of the study. Small sample size limited analyses and interpretation of study
findings to effect sizes and observed differences at the individual participant level. While some of
this was the result of the inclusion/exclusion criteria, the number that did not continue once
ascertained warrants further attention. It is possible that additional efforts to encourage and facilitate
patient engagement prior to medication initiation would bolster retention rates.
119

Complicating the challenges of participant burden is that current study only looked at the
effects of 2400mg of NAC daily on chronic neuropathic pain for 4 weeks. A 4-week active
medication period may be an insufficient length of time see and impact on long held beliefs about
pain, avoidance activities, and learned behaviors associated with long term chronic pain.
Additionally, a 4-week trial may not be long enough to impact a pattern of taking medication prior to
experiencing higher pain, as a means of prophylaxis.
Another limitation of the current study was the lack of a control group. The study was open
labeled, not controlled, and not randomized. In an open label study that has no control group,
participants are recruited to a known intervention with no risk of receiving placebo. Efficacy and
retention information is based on those receiving unblinded treatment. Findings thus far could be
significantly impacted by the addition of randomization and a placebo control.
Finally, the current study included participants with multiple concomitant medication,
including prescription, non-prescription, and medical/nutritional supplements. Use of concomitant
medications makes it impossible to determine whether treatment response was due to NAC alone or
its combination with other medications. Attempts to address this for the pain medication were made
by requiring a stable prescription of pain medication (opioid or gabapentin) and consistent PRN
prescription prior to study enrollment. Unfortunately, it was not feasible to require that participants
have stable medication regimens for medication unrelated to their pain. This raises the possibility
that changes in concomitant medications, used for unrelated medical or mental health conditions,
could be masking the treatment effects of NAC.

Study Strengths
Despite these limitations, the present study also has a number of strengths. This study adds
to a small, but growing, body of literature looking at the potential benefits of NAC. It is also one of
the only trials to date that has explored NAC as an adjuvant to traditional treatment for chronic
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neuropathic pain. The exploration of NAC as a nonopioid medication for chronic neuropathic pain
is timely given the recent recommendations from the CDC for the use of nonopioid therapy as the
preferred treatment for chronic pain (Dowell, Haegerich & Chou, 2016).
Another strength of this study was the focus on multiple domains associated with chronic
pain, including; medication usage, pain intensity, and physical and emotional functioning.
Collection of multiple measures allows for the multiple avenues to measure changes in pain related
to the novel medication. This approach allowed for observations in improvements of mental health
functioning even when the MED and pain ratings were nonspecific.
Another strength of the current study was the use of case studies to illustrate the range of
participant responses to the NAC medication. Case studies provided a comprehensive view of the
complex, real-life, experiences of patients with chronic neuropathic pain. Additionally, these case
studies allowed for an exploration of individual participant response to NAC across multiple
domains allowing for in-depth exploration of data from this small sample.
While difficult to recruit, once NAC was initiated we saw high rates of adherence and
retention. There were very few exclusionary criterion applied to patients in the present study,
beyond those necessary for safety, allowing for adequate sampling of typical neuropathic pain
patients with unmanaged, chronic pain.
A prominent strength of the current study is the role it can play to inform future, large scale,
studies through the lessons learned. The current study identified several challenges that future
researchers could face with recruitment, retention, and intervention and made suggestions on
directions and approaches that future research with NAC and chronic neuropathic pain could
explore.
Findings from the current study must be interpreted with caution. Nonetheless, while not
overwhelming, findings are promising. Individual report, effect sizes that were small but observable
in support of NAC for improving mental health QoL and pain ratings, and acceptability of NAC
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support the potential of NAC as a treatment adjuvant for chronic neuropathic pain. Application of
the lessons learned from the current study will benefit a larger, randomized control trial,
investigating the efficacy of NAC for chronic neuropathic pain. Given the severity of the problems
associated with chronic pain, as well as the potential harms associated with opioid pain medications,
NAC offers a well tolerated adjuvant to traditional chronic neuropathic pain management approaches
worthy of further exploration.
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Appendix
1. Daily Monitoring Form
2. Visual Analogue Scale
3. Pain Catastrophizing Scale
4. Patient Health Questionnaire-9 (PHQ-9)
5. Short Form-12 Health Survey Questionnaire (SF-12)

Daily Monitoring Form
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Visual Analogue Scale

Patient ID #:__________ Date:__/__/__

Visual Analogue Scale

We would like you to indicate on this scale the AVERAGE pain that you felt TODAY.
Please draw an line at whichever point on the scale indicates your AVERAGE pain for TODAY.

No Pain

Worst pain

Now we would like you to indicate on this scale the WORST pain that you have felt TODAY.
Please draw an line at whichever point on the scale indicates your WORST pain for TODAY.

No Pain

Worst pain
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Pain Catastrophizing Scale
Everyone experiences painful situations at some point in their lives. Such experiences may include
headaches, tooth pain, joint or muscle pain. People are often exposed to situations that may cause
pain such as illness, injury, dental procedures or surgery.

We are interested in the types of thoughts and feeling that you have when you are in pain. Listed
below are thirteen statements describing different thoughts and feelings that may be associated with
pain. Using the scale, please indicate the degree to which you have these thoughts and feelings
when you are experiencing pain.

Not at

To a

To a

To a

All the

all

slight

moderate

great

time

degree

degree

degree

0

1

2

3

4

I feel I can’t go on

0

1

2

3

4

It’s terrible and I think it’s never going to get

0

1

2

3

4

It’s awful and I feel that it overwhelms me

0

1

2

3

4

I feel I can’t stand it anymore

0

1

2

3

4

I become afraid that the pain will get worse

0

1

2

3

4

I keep thinking of other painful events

0

1

2

3

4

I anxiously want the pain to go away

0

1

2

3

4

I worry all the time about whether the pain will
end

any better
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I can’t seem to keep it out of my mind

0

1

2

3

4

I keep thinking about how much it hurts

0

1

2

3

4

I keep thinking about how badly I want the pain

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

to stop
There’s nothing I can do to reduce the intensity
of the pain
I wonder whether something serious may
happen

148

Patient Health Questionnaire-9 (PHQ-9)
PHQ-9

More

Over the last 2 weeks, how often have you been
Not at

Several

than half

Nearly

all

days

the days

every day

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself – or that you are a

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

bothered by any of the following problems?
(Use “X” to indicate your answer)

much

failure or have let yourself or your family down
7. Trouble concentrating on things, such as reading
the newspaper or watching television
8. Moving or speaking so slowly that other people
could have noticed? Or the opposite – being so
fidgety or restless that you have been moving
around a lot more than usual
9. Thoughts that you would be better off dead or of
hurting yourself in some way
2. If you checked off any problem on this questionnaire so far, how difficult have these
problems made it for you to do your work, take care of things at home, or get along with other
people? (PLEASE CIRCLE)
Not difficult at all

Somewhat difficult

Very difficult
149

Extremely difficult

150

Short Form-12 Health Survey Questionnaire (SF-12)

151

152

153
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